[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f3ZlcfcPKHEt1u-zyvbPKbGIBwMPPtkYb25ovMtM3pr0":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":34,"phaseBuckets":84,"rows":91},"Suzhou Suncadia Biopharmaceuticals Co., Ltd.",[4],88,false,63,26,20290,108,0,[14,17,20,23,25,28,30,32],{"name":15,"count":16},"Advanced Solid Tumors",11,{"name":18,"count":19},"Advanced Solid Tumor",4,{"name":21,"count":22},"Malignant Solid Tumors",3,{"name":24,"count":22},"Ovarian Cancer",{"name":26,"count":27},"Advanced Malignant Tumors",2,{"name":29,"count":27},"Psoriatic Arthritis",{"name":31,"count":27},"Biliary Tract Cancer",{"name":33,"count":27},"Advanced Non-small Cell Lung Cancer",[35,40,45,50,55,60,65,70,75,79],{"nctId":36,"briefTitle":37,"date":38,"intervention":39},"NCT04950322","A Trial of SHR1701 Plus Chemotherapy in Patients With Gastric or Gastroesophageal Cancer","2024-05-20","SHR-1701、CAPOX",{"nctId":41,"briefTitle":42,"date":43,"intervention":44},"NCT05300269","SHR-1701 in Combination With Chemotherapy and Radiotherapy in Locally Advanced Rectal Cancer","2024-07-31","SHR-1701；Capecitabine；Oxaliplatin",{"nctId":46,"briefTitle":47,"date":48,"intervention":49},"NCT05765032","Study of SHR-A1921 in Combination With Other Anti-cancer Agents in Patients With Advanced Solid Tumors","2025-04-30","SHR-A1921；",{"nctId":51,"briefTitle":52,"date":53,"intervention":54},"NCT05819684","A Study of SHR-4602 in Subjects With Advanced Malignant Solid Tumors","2025-05-30","SHR-4602 for",{"nctId":56,"briefTitle":57,"date":58,"intervention":59},"NCT07009457","Phase I Clinical Study of SHR-1316 (SC) Combined With Carboplatin and Etoposide as First-line Treatment for Extensive Stage Small Cell Lung Cancer","2025-09","SHR-1316 (sc)",{"nctId":61,"briefTitle":62,"date":63,"intervention":64},"NCT07028268","A Trial of SHR-2017 Injection in Patients With Bone Metastases From Solid Tumors","2025-12","SHR-2017、Denosumab placebo",{"nctId":66,"briefTitle":67,"date":68,"intervention":69},"NCT06247956","Study of SHR-8068 Combined With Adebrelimab and Platinum-containing Chemotherapy in the Treatment of Advanced Gastric and Esophageal Cancer","2025-12-30","SHR-8068;Adebrelimab;Oxaliplatin;Capecitabine Tablets;Paclitaxel Injection;Cisplatin",{"nctId":71,"briefTitle":72,"date":73,"intervention":74},"NCT06618651","A Study of SHR-3821 Injection in Subjects With Advanced Solid Tumors","2026-01-01","SHR-3821",{"nctId":76,"briefTitle":77,"date":73,"intervention":78},"NCT06703177","A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With Solid Tumors","SHR-1826",{"nctId":80,"briefTitle":81,"date":82,"intervention":83},"NCT06592625","Neoadjuvant SHR-A1811 Plus Adebrelimab in HR Negative\u002FLow & HER2 Low Breast Cancer Patients","2026-02-28","SHR-A1811",[85,86,87,88,89,90],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[92,120,257,332,386,440,487,524,583,676,702,735,757,788,816,844,862,880,905,923,941,965,987,1005,1031,1049,1067,1085,1103,1121,1147,1165,1191,1209,1227,1245,1263,1281,1299,1317,1335,1353,1371,1389,1407,1425,1443,1468,1486,1504,1522,1540,1581,1613,1639,1661,1681,1703,1721,1743,1761,1784,1802,1820,1845,1863,1881,1912,1930,1948,1966,1984,2002,2020,2038,2063,2089,2107,2125,2150,2168,2191,2213,2231,2255,2281,2299,2317,2335,2360,2378,2396,2414,2432,2450,2468,2489,2507,2529,2553,2578,2596,2617,2635,2658,2681,2699,2723,2747,2772,2797,2822,2847,2865,2891,2909,2943,2967,2985,3010,3033,3051,3085,3118,3141,3165,3189],{"intervention":93,"totalTrials":94,"cells":95},"Vunakizumab",1,{"EARLY_PHASE1":96,"PHASE1":98,"PHASE2":100,"PHASE3":102,"PHASE4":104,"NA":118},{"trials":97,"activeCount":12},[],{"trials":99,"activeCount":12},[],{"trials":101,"activeCount":12},[],{"trials":103,"activeCount":12},[],{"trials":105,"activeCount":94,"soonestReadout":111},[106],{"nctId":107,"briefTitle":108,"status":109,"phases":110,"primaryCompletion":111,"completion":112,"start":113,"enrollment":114,"conditions":115,"interventions":117},"NCT06779097","Phase IV Study: Vunakizumab Efficacy and Safety in Moderate-to-severe Plaque Psoriasis","NOT_YET_RECRUITING",[89],"2027-03","2028-02","2025-02",1564,[116],"Moderate to Severe Plaque Psoriasis",[93],{"trials":119,"activeCount":12},[],{"intervention":121,"totalTrials":122,"cells":123},"SHR-8068",10,{"EARLY_PHASE1":124,"PHASE1":126,"PHASE2":128,"PHASE3":227,"PHASE4":253,"NA":255},{"trials":125,"activeCount":12},[],{"trials":127,"activeCount":12},[],{"trials":129,"activeCount":226,"soonestReadout":73},[130,144,159,168,183,193,205,216],{"nctId":131,"briefTitle":132,"status":133,"phases":134,"primaryCompletion":135,"completion":135,"start":136,"enrollment":137,"conditions":138,"interventions":139},"NCT06465563","SHR-8068 in Combination With Adebrelimab, Bevacizumab, and Platinum-Based Chemotherapy as First-line Treatment in Patients With Advanced Biliary Tract Cancer","ACTIVE_NOT_RECRUITING",[87],"2026-12-30","2024-07-01",93,[31],[121,140,141,142,143],"Adebrelimab","Cisplatin","Gemcitabine","Bevacizumab",{"nctId":145,"briefTitle":146,"status":147,"phases":148,"primaryCompletion":149,"completion":150,"start":151,"enrollment":152,"conditions":153,"interventions":156},"NCT07110571","A Trial of Adebrelimab Plus (SHR-A1811\u002FSHR-A1904 With Chemotherapy) or SHR-8068 as Treatment for Gastric\u002FGEJ Cancer","RECRUITING",[87],"2026-08","2027-05","2025-08-28",200,[154,155],"Gastric Cancer","Gastroesophageal-junction Cancer",[140,157,158,121],"SHR-A1811 for","SHR-A1904 for",{"nctId":160,"briefTitle":161,"status":147,"phases":162,"primaryCompletion":163,"completion":163,"start":164,"enrollment":152,"conditions":165,"interventions":167},"NCT07071714","A Phase II Study of SHR-8068 Injection in Combination With Anti-tumor Therapies in Colorectal Cancer",[87],"2031-10","2025-07-22",[166],"Colorectal Cancer",[121,140,143],{"nctId":169,"briefTitle":170,"status":147,"phases":171,"primaryCompletion":172,"completion":172,"start":173,"enrollment":174,"conditions":175,"interventions":177},"NCT06754930","A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With NSCLC",[86,87],"2027-12","2025-02-18",400,[176],"Non-small Cell Lung Cancer (NSCLC)",[78,178,179,121,180,181,182],"SHR-1316","SHR-9839","Ametinib mesylate","BP-102","Carboplatin",{"nctId":184,"briefTitle":185,"status":147,"phases":186,"primaryCompletion":187,"completion":187,"start":188,"enrollment":189,"conditions":190,"interventions":192},"NCT05444088","Study of SHR-8068 Combined With Adebrelimab and Bevacizumab in the Treatment of Advanced Hepatocellular Carcinoma",[86,87],"2026-06-30","2022-08-02",129,[191],"Advanced Hepatocellular Carcinoma",[140,143,121],{"nctId":194,"briefTitle":195,"status":147,"phases":196,"primaryCompletion":197,"completion":198,"start":199,"enrollment":200,"conditions":201,"interventions":203},"NCT06859775","SHR-A1811 Combination Regimen for the Treatment of Recurrent or Metastatic Cervical Cancer",[86,87],"2026-10","2027-01","2025-04-25",100,[202],"Recurrent or Metastatic Cervical Cancer",[83,204,143,121,141,182],"Adebelimab",{"nctId":206,"briefTitle":207,"status":147,"phases":208,"primaryCompletion":209,"completion":210,"start":211,"enrollment":212,"conditions":213,"interventions":215},"NCT06778031","A Clinical Study of SHR-A1811 in the Treatment of HER2-positive Locally Advanced or Metastatic Biliary Tract Cancer",[87],"2028-06","2028-09","2025-02-26",54,[214],"HER2-positive Locally Advanced or Metastatic Biliary Tract Cancer",[83,178,121],{"nctId":76,"briefTitle":77,"status":147,"phases":217,"primaryCompletion":73,"completion":218,"start":173,"enrollment":219,"conditions":220,"interventions":221},[86,87],"2027-07-01",876,[15],[78,222,179,121,143,223,224,140,225],"SHR-4642","Fluorouracil","Calcium Folinate","Capecitabine",8,{"trials":228,"activeCount":27,"soonestReadout":245},[229,241],{"nctId":230,"briefTitle":231,"status":147,"phases":232,"primaryCompletion":233,"completion":233,"start":234,"enrollment":235,"conditions":236,"interventions":238},"NCT07229625","A Phase III Study of SHR-8068 in Combination With Adebrelimab and Platinum-Containing Chemotherapy Versus Durvalumab in Combination With Platinum-Containing Chemotherapy as First-line Treatment for Advanced Biliary Tract Cancer (BTC)",[88],"2029-12","2026-01-21",604,[237],"Advanced Biliary Tract Cancer",[121,140,239,141,240],"Gemcitabine Hydrochloride for","Durvalumab",{"nctId":242,"briefTitle":243,"status":147,"phases":244,"primaryCompletion":245,"completion":246,"start":247,"enrollment":248,"conditions":249,"interventions":250},"NCT06618664","A Clinical Study of SHR-8068 Combined With Adebrelimab and Bevacizumab Versus Sintilimab or Atezolizumab Combined With Bevacizumab for the Treatment of Advanced Hepatocellular Carcinoma",[88],"2026-09","2030-12","2024-10-28",590,[191],[121,140,143,251,252],"Sintilimab","Atezolizumab",{"trials":254,"activeCount":12},[],{"trials":256,"activeCount":12},[],{"intervention":140,"totalTrials":122,"cells":258},{"EARLY_PHASE1":259,"PHASE1":261,"PHASE2":263,"PHASE3":318,"PHASE4":328,"NA":330},{"trials":260,"activeCount":12},[],{"trials":262,"activeCount":12},[],{"trials":264,"activeCount":226,"soonestReadout":73},[265,269,273,277,281,294,301,314],{"nctId":131,"briefTitle":132,"status":133,"phases":266,"primaryCompletion":135,"completion":135,"start":136,"enrollment":137,"conditions":267,"interventions":268},[87],[31],[121,140,141,142,143],{"nctId":145,"briefTitle":146,"status":147,"phases":270,"primaryCompletion":149,"completion":150,"start":151,"enrollment":152,"conditions":271,"interventions":272},[87],[154,155],[140,157,158,121],{"nctId":160,"briefTitle":161,"status":147,"phases":274,"primaryCompletion":163,"completion":163,"start":164,"enrollment":152,"conditions":275,"interventions":276},[87],[166],[121,140,143],{"nctId":184,"briefTitle":185,"status":147,"phases":278,"primaryCompletion":187,"completion":187,"start":188,"enrollment":189,"conditions":279,"interventions":280},[86,87],[191],[140,143,121],{"nctId":282,"briefTitle":283,"status":147,"phases":284,"primaryCompletion":285,"completion":286,"start":287,"enrollment":288,"conditions":289,"interventions":291},"NCT07059221","A Trial of SHR-A2102 With Adebrelimab With or Without Other Anti-tumor Therapies in Recurrent\u002FMetastaticHead and Neck Squamous Cell Carcinoma Cancer",[86,87],"2026-03","2028-03","2025-07-11",96,[290],"Recurrent\u002FMetastatic Head and Neck Squamous Cell Carcinoma",[292,140,293],"SHR-A2102","Cetuximab",{"nctId":80,"briefTitle":81,"status":109,"phases":295,"primaryCompletion":82,"completion":82,"start":296,"enrollment":297,"conditions":298,"interventions":300},[87],"2024-09-20",60,[299],"Untreated Early-stage or Locally Advanced Breast Cancer",[83,140],{"nctId":302,"briefTitle":303,"status":147,"phases":304,"primaryCompletion":305,"completion":306,"start":307,"enrollment":308,"conditions":309,"interventions":310},"NCT06840002","A Clinical Study of SHR-A1811 Combined With Chemotherapy for Platinum Sensitive Recurrent Ovarian Cancer",[86,87],"2026-05","2026-07","2025-03-18",150,[24],[83,182,143,311,312,313,140],"Oxaliplatin for","Paclitaxel","Doxorubicin hydrochloride liposome",{"nctId":76,"briefTitle":77,"status":147,"phases":315,"primaryCompletion":73,"completion":218,"start":173,"enrollment":219,"conditions":316,"interventions":317},[86,87],[15],[78,222,179,121,143,223,224,140,225],{"trials":319,"activeCount":27,"soonestReadout":245},[320,324],{"nctId":230,"briefTitle":231,"status":147,"phases":321,"primaryCompletion":233,"completion":233,"start":234,"enrollment":235,"conditions":322,"interventions":323},[88],[237],[121,140,239,141,240],{"nctId":242,"briefTitle":243,"status":147,"phases":325,"primaryCompletion":245,"completion":246,"start":247,"enrollment":248,"conditions":326,"interventions":327},[88],[191],[121,140,143,251,252],{"trials":329,"activeCount":12},[],{"trials":331,"activeCount":12},[],{"intervention":143,"totalTrials":226,"cells":333},{"EARLY_PHASE1":334,"PHASE1":336,"PHASE2":349,"PHASE3":376,"PHASE4":382,"NA":384},{"trials":335,"activeCount":12},[],{"trials":337,"activeCount":94,"soonestReadout":342},[338],{"nctId":339,"briefTitle":340,"status":147,"phases":341,"primaryCompletion":342,"completion":172,"start":343,"enrollment":344,"conditions":345,"interventions":347},"NCT07478302","A Study of SHR-2524 Plus Bevacizumab in the First-line Treatment of Advanced Hepatocellular Carcinoma",[86],"2027-10","2026-04-14",36,[346],"Advanced Unresectable Hepatocellular Carcinoma",[348,143],"SHR-2524",{"trials":350,"activeCount":375,"soonestReadout":73},[351,355,359,363,367,371],{"nctId":131,"briefTitle":132,"status":133,"phases":352,"primaryCompletion":135,"completion":135,"start":136,"enrollment":137,"conditions":353,"interventions":354},[87],[31],[121,140,141,142,143],{"nctId":160,"briefTitle":161,"status":147,"phases":356,"primaryCompletion":163,"completion":163,"start":164,"enrollment":152,"conditions":357,"interventions":358},[87],[166],[121,140,143],{"nctId":184,"briefTitle":185,"status":147,"phases":360,"primaryCompletion":187,"completion":187,"start":188,"enrollment":189,"conditions":361,"interventions":362},[86,87],[191],[140,143,121],{"nctId":194,"briefTitle":195,"status":147,"phases":364,"primaryCompletion":197,"completion":198,"start":199,"enrollment":200,"conditions":365,"interventions":366},[86,87],[202],[83,204,143,121,141,182],{"nctId":302,"briefTitle":303,"status":147,"phases":368,"primaryCompletion":305,"completion":306,"start":307,"enrollment":308,"conditions":369,"interventions":370},[86,87],[24],[83,182,143,311,312,313,140],{"nctId":76,"briefTitle":77,"status":147,"phases":372,"primaryCompletion":73,"completion":218,"start":173,"enrollment":219,"conditions":373,"interventions":374},[86,87],[15],[78,222,179,121,143,223,224,140,225],6,{"trials":377,"activeCount":94,"soonestReadout":245},[378],{"nctId":242,"briefTitle":243,"status":147,"phases":379,"primaryCompletion":245,"completion":246,"start":247,"enrollment":248,"conditions":380,"interventions":381},[88],[191],[121,140,143,251,252],{"trials":383,"activeCount":12},[],{"trials":385,"activeCount":12},[],{"intervention":83,"totalTrials":375,"cells":387},{"EARLY_PHASE1":388,"PHASE1":390,"PHASE2":392,"PHASE3":422,"PHASE4":436,"NA":438},{"trials":389,"activeCount":12},[],{"trials":391,"activeCount":12},[],{"trials":393,"activeCount":19,"soonestReadout":82},[394,406,410,414,418],{"nctId":395,"briefTitle":396,"status":397,"phases":398,"primaryCompletion":399,"completion":400,"start":401,"enrollment":402,"conditions":403,"interventions":404},"NCT05349409","A Trial of the Combination of SHR-A1811 and Fluzoparib in HER2-Expressing Cancers","UNKNOWN",[87],"2024-11-30","2025-05-31","2022-06-09",212,[15],[83,405],"Fluzoparib",{"nctId":194,"briefTitle":195,"status":147,"phases":407,"primaryCompletion":197,"completion":198,"start":199,"enrollment":200,"conditions":408,"interventions":409},[86,87],[202],[83,204,143,121,141,182],{"nctId":206,"briefTitle":207,"status":147,"phases":411,"primaryCompletion":209,"completion":210,"start":211,"enrollment":212,"conditions":412,"interventions":413},[87],[214],[83,178,121],{"nctId":80,"briefTitle":81,"status":109,"phases":415,"primaryCompletion":82,"completion":82,"start":296,"enrollment":297,"conditions":416,"interventions":417},[87],[299],[83,140],{"nctId":302,"briefTitle":303,"status":147,"phases":419,"primaryCompletion":305,"completion":306,"start":307,"enrollment":308,"conditions":420,"interventions":421},[86,87],[24],[83,182,143,311,312,313,140],{"trials":423,"activeCount":94,"soonestReadout":428},[424],{"nctId":425,"briefTitle":426,"status":133,"phases":427,"primaryCompletion":428,"completion":429,"start":430,"enrollment":431,"conditions":432,"interventions":434},"NCT06199973","Injection of SHR-A1811 Versus Physician Choiced Treatment in Patients With Advanced Colorectal Cancer Who Had Failed to Respond to Oxaliplatin, 5-fu, and Irinotecan",[88],"2026-04","2026-06","2024-03-01",130,[433],"Advanced Colorectal Cancer",[83,435],"TAS-102, Regorafenib , Fruquintinib",{"trials":437,"activeCount":12},[],{"trials":439,"activeCount":12},[],{"intervention":182,"totalTrials":441,"cells":442},5,{"EARLY_PHASE1":443,"PHASE1":445,"PHASE2":455,"PHASE3":469,"PHASE4":483,"NA":485},{"trials":444,"activeCount":12},[],{"trials":446,"activeCount":94,"soonestReadout":58},[447],{"nctId":56,"briefTitle":57,"status":147,"phases":448,"primaryCompletion":58,"completion":210,"start":449,"enrollment":450,"conditions":451,"interventions":453},[86],"2025-06-16",48,[452],"Widespread Small Cell Lung Cancer",[59,178,182,454],"Etoposide",{"trials":456,"activeCount":22,"soonestReadout":305},[457,461,465],{"nctId":169,"briefTitle":170,"status":147,"phases":458,"primaryCompletion":172,"completion":172,"start":173,"enrollment":174,"conditions":459,"interventions":460},[86,87],[176],[78,178,179,121,180,181,182],{"nctId":194,"briefTitle":195,"status":147,"phases":462,"primaryCompletion":197,"completion":198,"start":199,"enrollment":200,"conditions":463,"interventions":464},[86,87],[202],[83,204,143,121,141,182],{"nctId":302,"briefTitle":303,"status":147,"phases":466,"primaryCompletion":305,"completion":306,"start":307,"enrollment":308,"conditions":467,"interventions":468},[86,87],[24],[83,182,143,311,312,313,140],{"trials":470,"activeCount":94,"soonestReadout":475},[471],{"nctId":472,"briefTitle":473,"status":109,"phases":474,"primaryCompletion":475,"completion":475,"start":476,"enrollment":477,"conditions":478,"interventions":479},"NCT06211023","A Study of SHR-A1921 With or Without Carboplatin in Subjects With Ovarian Cancer",[87,88],"2026-06-15","2024-02-15",520,[24],[480,481,481,482],"SHR-1921","carboplatin","platinum-based doublet chemotherapy",{"trials":484,"activeCount":12},[],{"trials":486,"activeCount":12},[],{"intervention":178,"totalTrials":19,"cells":488},{"EARLY_PHASE1":489,"PHASE1":491,"PHASE2":497,"PHASE3":507,"PHASE4":520,"NA":522},{"trials":490,"activeCount":12},[],{"trials":492,"activeCount":94,"soonestReadout":58},[493],{"nctId":56,"briefTitle":57,"status":147,"phases":494,"primaryCompletion":58,"completion":210,"start":449,"enrollment":450,"conditions":495,"interventions":496},[86],[452],[59,178,182,454],{"trials":498,"activeCount":27,"soonestReadout":172},[499,503],{"nctId":169,"briefTitle":170,"status":147,"phases":500,"primaryCompletion":172,"completion":172,"start":173,"enrollment":174,"conditions":501,"interventions":502},[86,87],[176],[78,178,179,121,180,181,182],{"nctId":206,"briefTitle":207,"status":147,"phases":504,"primaryCompletion":209,"completion":210,"start":211,"enrollment":212,"conditions":505,"interventions":506},[87],[214],[83,178,121],{"trials":508,"activeCount":94,"soonestReadout":286},[509],{"nctId":510,"briefTitle":511,"status":147,"phases":512,"primaryCompletion":286,"completion":513,"start":514,"enrollment":174,"conditions":515,"interventions":517},"NCT07111832","A Clinical Trial of SHR-A1811 in the Treatment of Triple-negative Breast Cancer",[88],"2028-12","2025-08-20",[516],"PD-L1-positive Locally Recurrent Unresectable or Metastatic Triple-negative Breast Cancer",[157,178,518,519],"Toripalimab","Paclitaxel for",{"trials":521,"activeCount":12},[],{"trials":523,"activeCount":12},[],{"intervention":239,"totalTrials":19,"cells":525},{"EARLY_PHASE1":526,"PHASE1":528,"PHASE2":530,"PHASE3":532,"PHASE4":579,"NA":581},{"trials":527,"activeCount":12},[],{"trials":529,"activeCount":12},[],{"trials":531,"activeCount":12},[],{"trials":533,"activeCount":19,"soonestReadout":111},[534,538,551,564],{"nctId":230,"briefTitle":231,"status":147,"phases":535,"primaryCompletion":233,"completion":233,"start":234,"enrollment":235,"conditions":536,"interventions":537},[88],[237],[121,140,239,141,240],{"nctId":539,"briefTitle":540,"status":147,"phases":541,"primaryCompletion":172,"completion":513,"start":542,"enrollment":543,"conditions":544,"interventions":547},"NCT07418749","A Study of SHR-A2102 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-based Chemotherapy and PD-(L)1 Inhibitor Treatment Failed Recurrent or Metastatic Cervical Cancer",[88],"2026-03-30",398,[545,546],"Recurrent Cervical Cancer","Metastatic Cervical Cancer",[548,549,239,550,519],"SHR-A2102 for","Pemetrexed Disodium for","Topotecan Hydrochloride for",{"nctId":552,"briefTitle":553,"status":147,"phases":554,"primaryCompletion":111,"completion":555,"start":556,"enrollment":557,"conditions":558,"interventions":560},"NCT06929624","A Phase 3 Clinical Study of SHR-A1912 Combined With R-GemOx Versus R-GemOx in Diffuse Large B-cell Lymphoma",[88],"2028-01","2025-04-24",280,[559],"Diffuse Large B-cell Lymphoma",[561,562,239,563],"SHR-A1912","Rituximab","Oxaliplatin",{"nctId":565,"briefTitle":566,"status":109,"phases":567,"primaryCompletion":568,"completion":568,"start":429,"enrollment":569,"conditions":570,"interventions":572},"NCT07424287","A Study of Intravesical SHR-1501 Combination With BCG Versus Investigator-selected Chemotherapy in Subjects With BCG-unresponsive NMIBC",[88],"2030-06",236,[571],"NMIBC",[573,574,575,576,239,577,578],"SHR-1501 for","BCG for","Epirubicin Hydrochloride for","Pirarubicin Hydrochloride for","Hydroxycamptothecin for","Mitomycin for",{"trials":580,"activeCount":12},[],{"trials":582,"activeCount":12},[],{"intervention":584,"totalTrials":226,"cells":585},"SHR-1314",{"EARLY_PHASE1":586,"PHASE1":588,"PHASE2":601,"PHASE3":633,"PHASE4":672,"NA":674},{"trials":587,"activeCount":12},[],{"trials":589,"activeCount":12},[590],{"nctId":591,"briefTitle":592,"status":593,"phases":594,"primaryCompletion":595,"completion":595,"start":596,"enrollment":597,"conditions":598,"interventions":600},"NCT06182384","A Clinical Study to Compare the Safety and Pharmacokinetics of SHR-1314 Injection in Healthy Subjects at Different Specifications Devices","COMPLETED",[86],"2024-05-13","2023-12-24",46,[599],"Moderate-to-Severe Plaque Psoriasis",[584,584],{"trials":602,"activeCount":12},[603,612,623],{"nctId":604,"briefTitle":605,"status":593,"phases":606,"primaryCompletion":607,"completion":607,"start":608,"enrollment":609,"conditions":610,"interventions":611},"NCT05055934","Study of the Effectiveness and Safety of SHR-1314 for Psoriatic Arthritis",[87],"2024-06-05","2021-10-22",112,[29],[584],{"nctId":613,"briefTitle":614,"status":615,"phases":616,"primaryCompletion":617,"completion":617,"start":618,"enrollment":619,"conditions":620,"interventions":622},"NCT05394857","Efficacy and Safety of SHR-1314 by Subcutaneous Injection in Active Moderate to Severe Graves' Orbitopathy Patients","TERMINATED",[87],"2023-08-22","2022-09-13",7,[621],"Active Moderate to Severe Graves' Orbitopathy",[584],{"nctId":624,"briefTitle":625,"status":397,"phases":626,"primaryCompletion":627,"completion":628,"start":629,"enrollment":297,"conditions":630,"interventions":632},"NCT04924296","A Phase II Study to Evaluate the Efficacy and Safety of SHR-1314 in Lupus Nephritis",[87],"2021-12-25","2022-09-03","2021-06-28",[631],"Lupus Nephritis",[584],{"trials":634,"activeCount":22,"soonestReadout":658},[635,643,654,662],{"nctId":636,"briefTitle":637,"status":109,"phases":638,"primaryCompletion":306,"completion":149,"start":113,"enrollment":639,"conditions":640,"interventions":642},"NCT06833307","The Efficacy and Safety of SHR-1314 in the Treatment of Pediatric Patients of Age 6 to \u003C18 Years With Moderate to Severe Plaque Psoriasis",[88],90,[641],"Children and Adolescents Aged 6 to 18 With Moderate-to-Severe Plaque Psoriasis",[584],{"nctId":644,"briefTitle":645,"status":593,"phases":646,"primaryCompletion":647,"completion":648,"start":649,"enrollment":650,"conditions":651,"interventions":653},"NCT04840485","Efficacy and Safety of SHR-1314 in Patients With Active Ankylosing Spondylitis",[87,88],"2023-11-03","2024-02-28","2021-06-09",548,[652],"Ankylosing Spondylitis",[584,584],{"nctId":655,"briefTitle":656,"status":147,"phases":657,"primaryCompletion":658,"completion":187,"start":659,"enrollment":152,"conditions":660,"interventions":661},"NCT06640257","A Study of the Efficacy and Safety of SHR-1314 for Adult Active Psoriatic Arthritis",[88],"2026-04-30","2024-11-04",[29],[584],{"nctId":663,"briefTitle":664,"status":147,"phases":665,"primaryCompletion":112,"completion":513,"start":666,"enrollment":667,"conditions":668,"interventions":670},"NCT06860750","A Trial of SHR-1314 Injection in Adult Patients With Active Non-radiographic Axial Spondyloarthritis",[88],"2025-04-29",380,[669],"Active Non-radiographic Axial Spondyloarthritis",[584,671],"SHR-1314 Placebo",{"trials":673,"activeCount":12},[],{"trials":675,"activeCount":12},[],{"intervention":141,"totalTrials":22,"cells":677},{"EARLY_PHASE1":678,"PHASE1":680,"PHASE2":682,"PHASE3":692,"PHASE4":698,"NA":700},{"trials":679,"activeCount":12},[],{"trials":681,"activeCount":12},[],{"trials":683,"activeCount":27,"soonestReadout":197},[684,688],{"nctId":131,"briefTitle":132,"status":133,"phases":685,"primaryCompletion":135,"completion":135,"start":136,"enrollment":137,"conditions":686,"interventions":687},[87],[31],[121,140,141,142,143],{"nctId":194,"briefTitle":195,"status":147,"phases":689,"primaryCompletion":197,"completion":198,"start":199,"enrollment":200,"conditions":690,"interventions":691},[86,87],[202],[83,204,143,121,141,182],{"trials":693,"activeCount":94,"soonestReadout":233},[694],{"nctId":230,"briefTitle":231,"status":147,"phases":695,"primaryCompletion":233,"completion":233,"start":234,"enrollment":235,"conditions":696,"interventions":697},[88],[237],[121,140,239,141,240],{"trials":699,"activeCount":12},[],{"trials":701,"activeCount":12},[],{"intervention":157,"totalTrials":22,"cells":703},{"EARLY_PHASE1":704,"PHASE1":706,"PHASE2":719,"PHASE3":725,"PHASE4":731,"NA":733},{"trials":705,"activeCount":12},[],{"trials":707,"activeCount":94,"soonestReadout":712},[708],{"nctId":709,"briefTitle":710,"status":147,"phases":711,"primaryCompletion":712,"completion":172,"start":713,"enrollment":714,"conditions":715,"interventions":717},"NCT07275242","A Clinical Study of SHR-A1811(sc) Subcutaneous Injection in Patients With Solid Tumor",[86],"2027-06","2025-12-23",107,[716],"Solid Tumor",[718,157],"SHR-A1811 Subcutaneous",{"trials":720,"activeCount":94,"soonestReadout":149},[721],{"nctId":145,"briefTitle":146,"status":147,"phases":722,"primaryCompletion":149,"completion":150,"start":151,"enrollment":152,"conditions":723,"interventions":724},[87],[154,155],[140,157,158,121],{"trials":726,"activeCount":94,"soonestReadout":286},[727],{"nctId":510,"briefTitle":511,"status":147,"phases":728,"primaryCompletion":286,"completion":513,"start":514,"enrollment":174,"conditions":729,"interventions":730},[88],[516],[157,178,518,519],{"trials":732,"activeCount":12},[],{"trials":734,"activeCount":12},[],{"intervention":519,"totalTrials":27,"cells":736},{"EARLY_PHASE1":737,"PHASE1":739,"PHASE2":741,"PHASE3":743,"PHASE4":753,"NA":755},{"trials":738,"activeCount":12},[],{"trials":740,"activeCount":12},[],{"trials":742,"activeCount":12},[],{"trials":744,"activeCount":27,"soonestReadout":172},[745,749],{"nctId":539,"briefTitle":540,"status":147,"phases":746,"primaryCompletion":172,"completion":513,"start":542,"enrollment":543,"conditions":747,"interventions":748},[88],[545,546],[548,549,239,550,519],{"nctId":510,"briefTitle":511,"status":147,"phases":750,"primaryCompletion":286,"completion":513,"start":514,"enrollment":174,"conditions":751,"interventions":752},[88],[516],[157,178,518,519],{"trials":754,"activeCount":12},[],{"trials":756,"activeCount":12},[],{"intervention":312,"totalTrials":27,"cells":758},{"EARLY_PHASE1":759,"PHASE1":761,"PHASE2":763,"PHASE3":769,"PHASE4":784,"NA":786},{"trials":760,"activeCount":12},[],{"trials":762,"activeCount":12},[],{"trials":764,"activeCount":94,"soonestReadout":305},[765],{"nctId":302,"briefTitle":303,"status":147,"phases":766,"primaryCompletion":305,"completion":306,"start":307,"enrollment":308,"conditions":767,"interventions":768},[86,87],[24],[83,182,143,311,312,313,140],{"trials":770,"activeCount":94,"soonestReadout":775},[771],{"nctId":772,"briefTitle":773,"status":147,"phases":774,"primaryCompletion":775,"completion":776,"start":777,"enrollment":778,"conditions":779,"interventions":780},"NCT06394492","SHR-A1921 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer",[88],"2026-05-31","2026-12-31","2024-05-10",440,[24],[781,782,312,783],"SHR-A1921","Doxorubicin","Topotecan",{"trials":785,"activeCount":12},[],{"trials":787,"activeCount":12},[],{"intervention":781,"totalTrials":27,"cells":789},{"EARLY_PHASE1":790,"PHASE1":792,"PHASE2":804,"PHASE3":806,"PHASE4":812,"NA":814},{"trials":791,"activeCount":12},[],{"trials":793,"activeCount":12},[794],{"nctId":795,"briefTitle":796,"status":397,"phases":797,"primaryCompletion":798,"completion":798,"start":799,"enrollment":800,"conditions":801,"interventions":803},"NCT05154604","A Study of SHR-A1921 for Injection in Subjects With Advanced Solid Tumours",[86],"2024-08-31","2021-12-31",156,[802],"Advanced Solid Tumours",[781],{"trials":805,"activeCount":12},[],{"trials":807,"activeCount":94,"soonestReadout":775},[808],{"nctId":772,"briefTitle":773,"status":147,"phases":809,"primaryCompletion":775,"completion":776,"start":777,"enrollment":778,"conditions":810,"interventions":811},[88],[24],[781,782,312,783],{"trials":813,"activeCount":12},[],{"trials":815,"activeCount":12},[],{"intervention":817,"totalTrials":94,"cells":818},"Adebrelimab in combination with SHR-8068 and chemotherapy",{"EARLY_PHASE1":819,"PHASE1":821,"PHASE2":823,"PHASE3":825,"PHASE4":840,"NA":842},{"trials":820,"activeCount":12},[],{"trials":822,"activeCount":12},[],{"trials":824,"activeCount":12},[],{"trials":826,"activeCount":94,"soonestReadout":831},[827],{"nctId":828,"briefTitle":829,"status":147,"phases":830,"primaryCompletion":831,"completion":832,"start":833,"enrollment":834,"conditions":835,"interventions":837},"NCT07454720","A Clinical Study of Adebrelimab in Combination With SHR-8068 and Chemoradiotherapy as Perioperative Therapy for Locally Advanced Rectal Cancer",[87,88],"2032-11","2035-11","2026-03-23",165,[836],"Locally Advanced Resectable Rectal Cancer",[817,838,839],"Adebrelimab combined with chemotherapy","Chemotherapy",{"trials":841,"activeCount":12},[],{"trials":843,"activeCount":12},[],{"intervention":838,"totalTrials":94,"cells":845},{"EARLY_PHASE1":846,"PHASE1":848,"PHASE2":850,"PHASE3":852,"PHASE4":858,"NA":860},{"trials":847,"activeCount":12},[],{"trials":849,"activeCount":12},[],{"trials":851,"activeCount":12},[],{"trials":853,"activeCount":94,"soonestReadout":831},[854],{"nctId":828,"briefTitle":829,"status":147,"phases":855,"primaryCompletion":831,"completion":832,"start":833,"enrollment":834,"conditions":856,"interventions":857},[87,88],[836],[817,838,839],{"trials":859,"activeCount":12},[],{"trials":861,"activeCount":12},[],{"intervention":839,"totalTrials":94,"cells":863},{"EARLY_PHASE1":864,"PHASE1":866,"PHASE2":868,"PHASE3":870,"PHASE4":876,"NA":878},{"trials":865,"activeCount":12},[],{"trials":867,"activeCount":12},[],{"trials":869,"activeCount":12},[],{"trials":871,"activeCount":94,"soonestReadout":831},[872],{"nctId":828,"briefTitle":829,"status":147,"phases":873,"primaryCompletion":831,"completion":832,"start":833,"enrollment":834,"conditions":874,"interventions":875},[87,88],[836],[817,838,839],{"trials":877,"activeCount":12},[],{"trials":879,"activeCount":12},[],{"intervention":881,"totalTrials":94,"cells":882},"SHR-8068，adebelizumab and platinum-based chemotherapy",{"EARLY_PHASE1":883,"PHASE1":885,"PHASE2":887,"PHASE3":889,"PHASE4":901,"NA":903},{"trials":884,"activeCount":12},[],{"trials":886,"activeCount":12},[],{"trials":888,"activeCount":12},[],{"trials":890,"activeCount":94,"soonestReadout":246},[891],{"nctId":892,"briefTitle":893,"status":147,"phases":894,"primaryCompletion":246,"completion":246,"start":895,"enrollment":896,"conditions":897,"interventions":899},"NCT07170995","Phase III Study of SHR-8068 Combined With Adebrelimab and Chemotherapy Versus Tislelizumab Combined With Chemotherapy in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer",[88],"2025-10-22",460,[898],"Advanced or Metastatic Non-small Cell Lung Cancer",[881,900],"tislelizumab, and platinum-based chemotherapy",{"trials":902,"activeCount":12},[],{"trials":904,"activeCount":12},[],{"intervention":900,"totalTrials":94,"cells":906},{"EARLY_PHASE1":907,"PHASE1":909,"PHASE2":911,"PHASE3":913,"PHASE4":919,"NA":921},{"trials":908,"activeCount":12},[],{"trials":910,"activeCount":12},[],{"trials":912,"activeCount":12},[],{"trials":914,"activeCount":94,"soonestReadout":246},[915],{"nctId":892,"briefTitle":893,"status":147,"phases":916,"primaryCompletion":246,"completion":246,"start":895,"enrollment":896,"conditions":917,"interventions":918},[88],[898],[881,900],{"trials":920,"activeCount":12},[],{"trials":922,"activeCount":12},[],{"intervention":435,"totalTrials":94,"cells":924},{"EARLY_PHASE1":925,"PHASE1":927,"PHASE2":929,"PHASE3":931,"PHASE4":937,"NA":939},{"trials":926,"activeCount":12},[],{"trials":928,"activeCount":12},[],{"trials":930,"activeCount":12},[],{"trials":932,"activeCount":94,"soonestReadout":428},[933],{"nctId":425,"briefTitle":426,"status":133,"phases":934,"primaryCompletion":428,"completion":429,"start":430,"enrollment":431,"conditions":935,"interventions":936},[88],[433],[83,435],{"trials":938,"activeCount":12},[],{"trials":940,"activeCount":12},[],{"intervention":942,"totalTrials":94,"cells":943},"SHR-A2102；Adebrelimab",{"EARLY_PHASE1":944,"PHASE1":946,"PHASE2":948,"PHASE3":950,"PHASE4":961,"NA":963},{"trials":945,"activeCount":12},[],{"trials":947,"activeCount":12},[],{"trials":949,"activeCount":12},[],{"trials":951,"activeCount":94,"soonestReadout":956},[952],{"nctId":953,"briefTitle":954,"status":147,"phases":955,"primaryCompletion":956,"completion":956,"start":199,"enrollment":957,"conditions":958,"interventions":960},"NCT06879145","Clinical Study on the Treatment of MIBC Patients With SHR-A2102 Injection Combined With Adebrelimab (SHR-1316)",[87,88],"2031-12",840,[959],"Muscular Invasive Bladder Cancer (MIBC)",[942],{"trials":962,"activeCount":12},[],{"trials":964,"activeCount":12},[],{"intervention":39,"totalTrials":94,"cells":966},{"EARLY_PHASE1":967,"PHASE1":969,"PHASE2":971,"PHASE3":973,"PHASE4":983,"NA":985},{"trials":968,"activeCount":12},[],{"trials":970,"activeCount":12},[],{"trials":972,"activeCount":12},[],{"trials":974,"activeCount":94,"soonestReadout":38},[975],{"nctId":36,"briefTitle":37,"status":133,"phases":976,"primaryCompletion":38,"completion":977,"start":978,"enrollment":979,"conditions":980,"interventions":982},[88],"2025-10-01","2021-12-06",737,[981],"Gastric or Gastroesophageal Junction Cancer",[39],{"trials":984,"activeCount":12},[],{"trials":986,"activeCount":12},[],{"intervention":240,"totalTrials":94,"cells":988},{"EARLY_PHASE1":989,"PHASE1":991,"PHASE2":993,"PHASE3":995,"PHASE4":1001,"NA":1003},{"trials":990,"activeCount":12},[],{"trials":992,"activeCount":12},[],{"trials":994,"activeCount":12},[],{"trials":996,"activeCount":94,"soonestReadout":233},[997],{"nctId":230,"briefTitle":231,"status":147,"phases":998,"primaryCompletion":233,"completion":233,"start":234,"enrollment":235,"conditions":999,"interventions":1000},[88],[237],[121,140,239,141,240],{"trials":1002,"activeCount":12},[],{"trials":1004,"activeCount":12},[],{"intervention":1006,"totalTrials":94,"cells":1007},"SHR-A1811 + Adebrelimab Injection + Capecitabine Tablets or Fluorouracil",{"EARLY_PHASE1":1008,"PHASE1":1010,"PHASE2":1012,"PHASE3":1014,"PHASE4":1027,"NA":1029},{"trials":1009,"activeCount":12},[],{"trials":1011,"activeCount":12},[],{"trials":1013,"activeCount":12},[],{"trials":1015,"activeCount":94,"soonestReadout":1020},[1016],{"nctId":1017,"briefTitle":1018,"status":147,"phases":1019,"primaryCompletion":1020,"completion":1020,"start":1021,"enrollment":1022,"conditions":1023,"interventions":1025},"NCT07118527","A Phase III Study of SHR-A1811 in Combination With Chemotherapy and Adebrelimab in Previously Untreated Patients With Gastric or Gastroesophageal Junction Adenocarcinoma",[88],"2030-10","2025-08-18",600,[1024],"Patients With Unresectable Locally Advanced or Metastatic Untreated Gastric or Gastroesophageal Junction Adenocarcinoma",[1006,1026],"Trastuzumab + Pembrolizumab + CAPOX",{"trials":1028,"activeCount":12},[],{"trials":1030,"activeCount":12},[],{"intervention":1026,"totalTrials":94,"cells":1032},{"EARLY_PHASE1":1033,"PHASE1":1035,"PHASE2":1037,"PHASE3":1039,"PHASE4":1045,"NA":1047},{"trials":1034,"activeCount":12},[],{"trials":1036,"activeCount":12},[],{"trials":1038,"activeCount":12},[],{"trials":1040,"activeCount":94,"soonestReadout":1020},[1041],{"nctId":1017,"briefTitle":1018,"status":147,"phases":1042,"primaryCompletion":1020,"completion":1020,"start":1021,"enrollment":1022,"conditions":1043,"interventions":1044},[88],[1024],[1006,1026],{"trials":1046,"activeCount":12},[],{"trials":1048,"activeCount":12},[],{"intervention":548,"totalTrials":94,"cells":1050},{"EARLY_PHASE1":1051,"PHASE1":1053,"PHASE2":1055,"PHASE3":1057,"PHASE4":1063,"NA":1065},{"trials":1052,"activeCount":12},[],{"trials":1054,"activeCount":12},[],{"trials":1056,"activeCount":12},[],{"trials":1058,"activeCount":94,"soonestReadout":172},[1059],{"nctId":539,"briefTitle":540,"status":147,"phases":1060,"primaryCompletion":172,"completion":513,"start":542,"enrollment":543,"conditions":1061,"interventions":1062},[88],[545,546],[548,549,239,550,519],{"trials":1064,"activeCount":12},[],{"trials":1066,"activeCount":12},[],{"intervention":549,"totalTrials":94,"cells":1068},{"EARLY_PHASE1":1069,"PHASE1":1071,"PHASE2":1073,"PHASE3":1075,"PHASE4":1081,"NA":1083},{"trials":1070,"activeCount":12},[],{"trials":1072,"activeCount":12},[],{"trials":1074,"activeCount":12},[],{"trials":1076,"activeCount":94,"soonestReadout":172},[1077],{"nctId":539,"briefTitle":540,"status":147,"phases":1078,"primaryCompletion":172,"completion":513,"start":542,"enrollment":543,"conditions":1079,"interventions":1080},[88],[545,546],[548,549,239,550,519],{"trials":1082,"activeCount":12},[],{"trials":1084,"activeCount":12},[],{"intervention":550,"totalTrials":94,"cells":1086},{"EARLY_PHASE1":1087,"PHASE1":1089,"PHASE2":1091,"PHASE3":1093,"PHASE4":1099,"NA":1101},{"trials":1088,"activeCount":12},[],{"trials":1090,"activeCount":12},[],{"trials":1092,"activeCount":12},[],{"trials":1094,"activeCount":94,"soonestReadout":172},[1095],{"nctId":539,"briefTitle":540,"status":147,"phases":1096,"primaryCompletion":172,"completion":513,"start":542,"enrollment":543,"conditions":1097,"interventions":1098},[88],[545,546],[548,549,239,550,519],{"trials":1100,"activeCount":12},[],{"trials":1102,"activeCount":12},[],{"intervention":671,"totalTrials":94,"cells":1104},{"EARLY_PHASE1":1105,"PHASE1":1107,"PHASE2":1109,"PHASE3":1111,"PHASE4":1117,"NA":1119},{"trials":1106,"activeCount":12},[],{"trials":1108,"activeCount":12},[],{"trials":1110,"activeCount":12},[],{"trials":1112,"activeCount":94,"soonestReadout":112},[1113],{"nctId":663,"briefTitle":664,"status":147,"phases":1114,"primaryCompletion":112,"completion":513,"start":666,"enrollment":667,"conditions":1115,"interventions":1116},[88],[669],[584,671],{"trials":1118,"activeCount":12},[],{"trials":1120,"activeCount":12},[],{"intervention":1122,"totalTrials":94,"cells":1123},"SHR-A2009 monotherapy",{"EARLY_PHASE1":1124,"PHASE1":1126,"PHASE2":1128,"PHASE3":1130,"PHASE4":1143,"NA":1145},{"trials":1125,"activeCount":12},[],{"trials":1127,"activeCount":12},[],{"trials":1129,"activeCount":12},[],{"trials":1131,"activeCount":94,"soonestReadout":1136},[1132],{"nctId":1133,"briefTitle":1134,"status":133,"phases":1135,"primaryCompletion":1136,"completion":712,"start":1137,"enrollment":1138,"conditions":1139,"interventions":1141},"NCT06671379","A Study of SHR-A2009 Versus Platinum-based Chemotherapy in EGFR-mutated, Advanced or Metastatic NSCLC",[88],"2026-12","2024-11-29",498,[1140],"Non-small Cell Lung Cancer",[1122,1142],"platinum-based dual-agent chemotherapy",{"trials":1144,"activeCount":12},[],{"trials":1146,"activeCount":12},[],{"intervention":1142,"totalTrials":94,"cells":1148},{"EARLY_PHASE1":1149,"PHASE1":1151,"PHASE2":1153,"PHASE3":1155,"PHASE4":1161,"NA":1163},{"trials":1150,"activeCount":12},[],{"trials":1152,"activeCount":12},[],{"trials":1154,"activeCount":12},[],{"trials":1156,"activeCount":94,"soonestReadout":1136},[1157],{"nctId":1133,"briefTitle":1134,"status":133,"phases":1158,"primaryCompletion":1136,"completion":712,"start":1137,"enrollment":1138,"conditions":1159,"interventions":1160},[88],[1140],[1122,1142],{"trials":1162,"activeCount":12},[],{"trials":1164,"activeCount":12},[],{"intervention":1166,"totalTrials":94,"cells":1167},"SHR-A2102 and Adebrelimab",{"EARLY_PHASE1":1168,"PHASE1":1170,"PHASE2":1172,"PHASE3":1174,"PHASE4":1187,"NA":1189},{"trials":1169,"activeCount":12},[],{"trials":1171,"activeCount":12},[],{"trials":1173,"activeCount":12},[],{"trials":1175,"activeCount":94,"soonestReadout":1180},[1176],{"nctId":1177,"briefTitle":1178,"status":147,"phases":1179,"primaryCompletion":1180,"completion":568,"start":1181,"enrollment":1182,"conditions":1183,"interventions":1185},"NCT07393542","A Trial of SHR-A2102 With Adebrelimab in Locally Advanced or Metastatic Urothelial Carcinoma",[88],"2027-09","2026-02-12",462,[1184],"Locally Advanced or Metastatic Urothelial Carcinoma",[1166,1186],"Gemcitabine and cisplatin \u002F carboplatin",{"trials":1188,"activeCount":12},[],{"trials":1190,"activeCount":12},[],{"intervention":1186,"totalTrials":94,"cells":1192},{"EARLY_PHASE1":1193,"PHASE1":1195,"PHASE2":1197,"PHASE3":1199,"PHASE4":1205,"NA":1207},{"trials":1194,"activeCount":12},[],{"trials":1196,"activeCount":12},[],{"trials":1198,"activeCount":12},[],{"trials":1200,"activeCount":94,"soonestReadout":1180},[1201],{"nctId":1177,"briefTitle":1178,"status":147,"phases":1202,"primaryCompletion":1180,"completion":568,"start":1181,"enrollment":1182,"conditions":1203,"interventions":1204},[88],[1184],[1166,1186],{"trials":1206,"activeCount":12},[],{"trials":1208,"activeCount":12},[],{"intervention":561,"totalTrials":94,"cells":1210},{"EARLY_PHASE1":1211,"PHASE1":1213,"PHASE2":1215,"PHASE3":1217,"PHASE4":1223,"NA":1225},{"trials":1212,"activeCount":12},[],{"trials":1214,"activeCount":12},[],{"trials":1216,"activeCount":12},[],{"trials":1218,"activeCount":94,"soonestReadout":111},[1219],{"nctId":552,"briefTitle":553,"status":147,"phases":1220,"primaryCompletion":111,"completion":555,"start":556,"enrollment":557,"conditions":1221,"interventions":1222},[88],[559],[561,562,239,563],{"trials":1224,"activeCount":12},[],{"trials":1226,"activeCount":12},[],{"intervention":562,"totalTrials":94,"cells":1228},{"EARLY_PHASE1":1229,"PHASE1":1231,"PHASE2":1233,"PHASE3":1235,"PHASE4":1241,"NA":1243},{"trials":1230,"activeCount":12},[],{"trials":1232,"activeCount":12},[],{"trials":1234,"activeCount":12},[],{"trials":1236,"activeCount":94,"soonestReadout":111},[1237],{"nctId":552,"briefTitle":553,"status":147,"phases":1238,"primaryCompletion":111,"completion":555,"start":556,"enrollment":557,"conditions":1239,"interventions":1240},[88],[559],[561,562,239,563],{"trials":1242,"activeCount":12},[],{"trials":1244,"activeCount":12},[],{"intervention":563,"totalTrials":94,"cells":1246},{"EARLY_PHASE1":1247,"PHASE1":1249,"PHASE2":1251,"PHASE3":1253,"PHASE4":1259,"NA":1261},{"trials":1248,"activeCount":12},[],{"trials":1250,"activeCount":12},[],{"trials":1252,"activeCount":12},[],{"trials":1254,"activeCount":94,"soonestReadout":111},[1255],{"nctId":552,"briefTitle":553,"status":147,"phases":1256,"primaryCompletion":111,"completion":555,"start":556,"enrollment":557,"conditions":1257,"interventions":1258},[88],[559],[561,562,239,563],{"trials":1260,"activeCount":12},[],{"trials":1262,"activeCount":12},[],{"intervention":573,"totalTrials":94,"cells":1264},{"EARLY_PHASE1":1265,"PHASE1":1267,"PHASE2":1269,"PHASE3":1271,"PHASE4":1277,"NA":1279},{"trials":1266,"activeCount":12},[],{"trials":1268,"activeCount":12},[],{"trials":1270,"activeCount":12},[],{"trials":1272,"activeCount":94,"soonestReadout":568},[1273],{"nctId":565,"briefTitle":566,"status":109,"phases":1274,"primaryCompletion":568,"completion":568,"start":429,"enrollment":569,"conditions":1275,"interventions":1276},[88],[571],[573,574,575,576,239,577,578],{"trials":1278,"activeCount":12},[],{"trials":1280,"activeCount":12},[],{"intervention":574,"totalTrials":94,"cells":1282},{"EARLY_PHASE1":1283,"PHASE1":1285,"PHASE2":1287,"PHASE3":1289,"PHASE4":1295,"NA":1297},{"trials":1284,"activeCount":12},[],{"trials":1286,"activeCount":12},[],{"trials":1288,"activeCount":12},[],{"trials":1290,"activeCount":94,"soonestReadout":568},[1291],{"nctId":565,"briefTitle":566,"status":109,"phases":1292,"primaryCompletion":568,"completion":568,"start":429,"enrollment":569,"conditions":1293,"interventions":1294},[88],[571],[573,574,575,576,239,577,578],{"trials":1296,"activeCount":12},[],{"trials":1298,"activeCount":12},[],{"intervention":575,"totalTrials":94,"cells":1300},{"EARLY_PHASE1":1301,"PHASE1":1303,"PHASE2":1305,"PHASE3":1307,"PHASE4":1313,"NA":1315},{"trials":1302,"activeCount":12},[],{"trials":1304,"activeCount":12},[],{"trials":1306,"activeCount":12},[],{"trials":1308,"activeCount":94,"soonestReadout":568},[1309],{"nctId":565,"briefTitle":566,"status":109,"phases":1310,"primaryCompletion":568,"completion":568,"start":429,"enrollment":569,"conditions":1311,"interventions":1312},[88],[571],[573,574,575,576,239,577,578],{"trials":1314,"activeCount":12},[],{"trials":1316,"activeCount":12},[],{"intervention":576,"totalTrials":94,"cells":1318},{"EARLY_PHASE1":1319,"PHASE1":1321,"PHASE2":1323,"PHASE3":1325,"PHASE4":1331,"NA":1333},{"trials":1320,"activeCount":12},[],{"trials":1322,"activeCount":12},[],{"trials":1324,"activeCount":12},[],{"trials":1326,"activeCount":94,"soonestReadout":568},[1327],{"nctId":565,"briefTitle":566,"status":109,"phases":1328,"primaryCompletion":568,"completion":568,"start":429,"enrollment":569,"conditions":1329,"interventions":1330},[88],[571],[573,574,575,576,239,577,578],{"trials":1332,"activeCount":12},[],{"trials":1334,"activeCount":12},[],{"intervention":577,"totalTrials":94,"cells":1336},{"EARLY_PHASE1":1337,"PHASE1":1339,"PHASE2":1341,"PHASE3":1343,"PHASE4":1349,"NA":1351},{"trials":1338,"activeCount":12},[],{"trials":1340,"activeCount":12},[],{"trials":1342,"activeCount":12},[],{"trials":1344,"activeCount":94,"soonestReadout":568},[1345],{"nctId":565,"briefTitle":566,"status":109,"phases":1346,"primaryCompletion":568,"completion":568,"start":429,"enrollment":569,"conditions":1347,"interventions":1348},[88],[571],[573,574,575,576,239,577,578],{"trials":1350,"activeCount":12},[],{"trials":1352,"activeCount":12},[],{"intervention":578,"totalTrials":94,"cells":1354},{"EARLY_PHASE1":1355,"PHASE1":1357,"PHASE2":1359,"PHASE3":1361,"PHASE4":1367,"NA":1369},{"trials":1356,"activeCount":12},[],{"trials":1358,"activeCount":12},[],{"trials":1360,"activeCount":12},[],{"trials":1362,"activeCount":94,"soonestReadout":568},[1363],{"nctId":565,"briefTitle":566,"status":109,"phases":1364,"primaryCompletion":568,"completion":568,"start":429,"enrollment":569,"conditions":1365,"interventions":1366},[88],[571],[573,574,575,576,239,577,578],{"trials":1368,"activeCount":12},[],{"trials":1370,"activeCount":12},[],{"intervention":480,"totalTrials":94,"cells":1372},{"EARLY_PHASE1":1373,"PHASE1":1375,"PHASE2":1377,"PHASE3":1379,"PHASE4":1385,"NA":1387},{"trials":1374,"activeCount":12},[],{"trials":1376,"activeCount":12},[],{"trials":1378,"activeCount":12},[],{"trials":1380,"activeCount":94,"soonestReadout":475},[1381],{"nctId":472,"briefTitle":473,"status":109,"phases":1382,"primaryCompletion":475,"completion":475,"start":476,"enrollment":477,"conditions":1383,"interventions":1384},[87,88],[24],[480,481,481,482],{"trials":1386,"activeCount":12},[],{"trials":1388,"activeCount":12},[],{"intervention":482,"totalTrials":94,"cells":1390},{"EARLY_PHASE1":1391,"PHASE1":1393,"PHASE2":1395,"PHASE3":1397,"PHASE4":1403,"NA":1405},{"trials":1392,"activeCount":12},[],{"trials":1394,"activeCount":12},[],{"trials":1396,"activeCount":12},[],{"trials":1398,"activeCount":94,"soonestReadout":475},[1399],{"nctId":472,"briefTitle":473,"status":109,"phases":1400,"primaryCompletion":475,"completion":475,"start":476,"enrollment":477,"conditions":1401,"interventions":1402},[87,88],[24],[480,481,481,482],{"trials":1404,"activeCount":12},[],{"trials":1406,"activeCount":12},[],{"intervention":251,"totalTrials":94,"cells":1408},{"EARLY_PHASE1":1409,"PHASE1":1411,"PHASE2":1413,"PHASE3":1415,"PHASE4":1421,"NA":1423},{"trials":1410,"activeCount":12},[],{"trials":1412,"activeCount":12},[],{"trials":1414,"activeCount":12},[],{"trials":1416,"activeCount":94,"soonestReadout":245},[1417],{"nctId":242,"briefTitle":243,"status":147,"phases":1418,"primaryCompletion":245,"completion":246,"start":247,"enrollment":248,"conditions":1419,"interventions":1420},[88],[191],[121,140,143,251,252],{"trials":1422,"activeCount":12},[],{"trials":1424,"activeCount":12},[],{"intervention":252,"totalTrials":94,"cells":1426},{"EARLY_PHASE1":1427,"PHASE1":1429,"PHASE2":1431,"PHASE3":1433,"PHASE4":1439,"NA":1441},{"trials":1428,"activeCount":12},[],{"trials":1430,"activeCount":12},[],{"trials":1432,"activeCount":12},[],{"trials":1434,"activeCount":94,"soonestReadout":245},[1435],{"nctId":242,"briefTitle":243,"status":147,"phases":1436,"primaryCompletion":245,"completion":246,"start":247,"enrollment":248,"conditions":1437,"interventions":1438},[88],[191],[121,140,143,251,252],{"trials":1440,"activeCount":12},[],{"trials":1442,"activeCount":12},[],{"intervention":1444,"totalTrials":94,"cells":1445},"SHR-A2009 ; Aumolertinib",{"EARLY_PHASE1":1446,"PHASE1":1448,"PHASE2":1450,"PHASE3":1452,"PHASE4":1464,"NA":1466},{"trials":1447,"activeCount":12},[],{"trials":1449,"activeCount":12},[],{"trials":1451,"activeCount":12},[],{"trials":1453,"activeCount":94,"soonestReadout":831},[1454],{"nctId":1455,"briefTitle":1456,"status":147,"phases":1457,"primaryCompletion":831,"completion":1458,"start":1459,"enrollment":1460,"conditions":1461,"interventions":1462},"NCT07183189","A Study of SHR-A2009 Combined With Aumolertinib Versus Aumolertinib for First-line Treatment in EGFR-mutated, Advanced or Metastatic NSCLC",[88],"2032-12","2025-10-30",576,[1140],[1444,1463],"Aumolertinib",{"trials":1465,"activeCount":12},[],{"trials":1467,"activeCount":12},[],{"intervention":1463,"totalTrials":94,"cells":1469},{"EARLY_PHASE1":1470,"PHASE1":1472,"PHASE2":1474,"PHASE3":1476,"PHASE4":1482,"NA":1484},{"trials":1471,"activeCount":12},[],{"trials":1473,"activeCount":12},[],{"trials":1475,"activeCount":12},[],{"trials":1477,"activeCount":94,"soonestReadout":831},[1478],{"nctId":1455,"briefTitle":1456,"status":147,"phases":1479,"primaryCompletion":831,"completion":1458,"start":1459,"enrollment":1460,"conditions":1480,"interventions":1481},[88],[1140],[1444,1463],{"trials":1483,"activeCount":12},[],{"trials":1485,"activeCount":12},[],{"intervention":518,"totalTrials":94,"cells":1487},{"EARLY_PHASE1":1488,"PHASE1":1490,"PHASE2":1492,"PHASE3":1494,"PHASE4":1500,"NA":1502},{"trials":1489,"activeCount":12},[],{"trials":1491,"activeCount":12},[],{"trials":1493,"activeCount":12},[],{"trials":1495,"activeCount":94,"soonestReadout":286},[1496],{"nctId":510,"briefTitle":511,"status":147,"phases":1497,"primaryCompletion":286,"completion":513,"start":514,"enrollment":174,"conditions":1498,"interventions":1499},[88],[516],[157,178,518,519],{"trials":1501,"activeCount":12},[],{"trials":1503,"activeCount":12},[],{"intervention":782,"totalTrials":94,"cells":1505},{"EARLY_PHASE1":1506,"PHASE1":1508,"PHASE2":1510,"PHASE3":1512,"PHASE4":1518,"NA":1520},{"trials":1507,"activeCount":12},[],{"trials":1509,"activeCount":12},[],{"trials":1511,"activeCount":12},[],{"trials":1513,"activeCount":94,"soonestReadout":775},[1514],{"nctId":772,"briefTitle":773,"status":147,"phases":1515,"primaryCompletion":775,"completion":776,"start":777,"enrollment":778,"conditions":1516,"interventions":1517},[88],[24],[781,782,312,783],{"trials":1519,"activeCount":12},[],{"trials":1521,"activeCount":12},[],{"intervention":783,"totalTrials":94,"cells":1523},{"EARLY_PHASE1":1524,"PHASE1":1526,"PHASE2":1528,"PHASE3":1530,"PHASE4":1536,"NA":1538},{"trials":1525,"activeCount":12},[],{"trials":1527,"activeCount":12},[],{"trials":1529,"activeCount":12},[],{"trials":1531,"activeCount":94,"soonestReadout":775},[1532],{"nctId":772,"briefTitle":773,"status":147,"phases":1533,"primaryCompletion":775,"completion":776,"start":777,"enrollment":778,"conditions":1534,"interventions":1535},[88],[24],[781,782,312,783],{"trials":1537,"activeCount":12},[],{"trials":1539,"activeCount":12},[],{"intervention":78,"totalTrials":19,"cells":1541},{"EARLY_PHASE1":1542,"PHASE1":1544,"PHASE2":1556,"PHASE3":1575,"PHASE4":1577,"NA":1579},{"trials":1543,"activeCount":12},[],{"trials":1545,"activeCount":94,"soonestReadout":1550},[1546],{"nctId":1547,"briefTitle":1548,"status":147,"phases":1549,"primaryCompletion":1550,"completion":1551,"start":1552,"enrollment":1553,"conditions":1554,"interventions":1555},"NCT06094556","An Open Phase I Clinical Trial of SHR-1826 for Injection in Patients With Advanced Solid Tumors",[86],"2027-06-30","2027-07-31","2023-12-25",240,[15],[78],{"trials":1557,"activeCount":22,"soonestReadout":73},[1558,1562,1571],{"nctId":169,"briefTitle":170,"status":147,"phases":1559,"primaryCompletion":172,"completion":172,"start":173,"enrollment":174,"conditions":1560,"interventions":1561},[86,87],[176],[78,178,179,121,180,181,182],{"nctId":1563,"briefTitle":1564,"status":147,"phases":1565,"primaryCompletion":1566,"completion":513,"start":1567,"enrollment":639,"conditions":1568,"interventions":1570},"NCT07489716","A Phase II Clinical Trial of SHR-1826 for Non-Small Cell Lung Cancer",[87],"2028-08","2026-04-29",[1569],"Non-Small Cell Lung Cancer",[78],{"nctId":76,"briefTitle":77,"status":147,"phases":1572,"primaryCompletion":73,"completion":218,"start":173,"enrollment":219,"conditions":1573,"interventions":1574},[86,87],[15],[78,222,179,121,143,223,224,140,225],{"trials":1576,"activeCount":12},[],{"trials":1578,"activeCount":12},[],{"trials":1580,"activeCount":12},[],{"intervention":1582,"totalTrials":27,"cells":1583},"SHR-4375",{"EARLY_PHASE1":1584,"PHASE1":1586,"PHASE2":1588,"PHASE3":1607,"PHASE4":1609,"NA":1611},{"trials":1585,"activeCount":12},[],{"trials":1587,"activeCount":12},[],{"trials":1589,"activeCount":27,"soonestReadout":198},[1590,1598],{"nctId":1591,"briefTitle":1592,"status":147,"phases":1593,"primaryCompletion":198,"completion":555,"start":1594,"enrollment":1595,"conditions":1596,"interventions":1597},"NCT07298772","A Study of SHR-4375 Injection in Combination With Other Antitumor Therapies in Patients With Solid Tumors",[86,87],"2026-01-07",198,[18],[1582],{"nctId":1599,"briefTitle":1600,"status":147,"phases":1601,"primaryCompletion":150,"completion":150,"start":1602,"enrollment":1603,"conditions":1604,"interventions":1606},"NCT06764628","A Study of SHR-4375 in Subjects With Solid Tumors",[86,87],"2025-01-09",208,[1605],"Solid Tumors",[1582],{"trials":1608,"activeCount":12},[],{"trials":1610,"activeCount":12},[],{"trials":1612,"activeCount":12},[],{"intervention":158,"totalTrials":27,"cells":1614},{"EARLY_PHASE1":1615,"PHASE1":1617,"PHASE2":1619,"PHASE3":1633,"PHASE4":1635,"NA":1637},{"trials":1616,"activeCount":12},[],{"trials":1618,"activeCount":12},[],{"trials":1620,"activeCount":27,"soonestReadout":149},[1621,1625],{"nctId":145,"briefTitle":146,"status":147,"phases":1622,"primaryCompletion":149,"completion":150,"start":151,"enrollment":152,"conditions":1623,"interventions":1624},[87],[154,155],[140,157,158,121],{"nctId":1626,"briefTitle":1627,"status":147,"phases":1628,"primaryCompletion":246,"completion":246,"start":1629,"enrollment":1630,"conditions":1631,"interventions":1632},"NCT07450976","A Study of SHR-A1904 in Previous Systemic Treatment Failed Biliary Tract Cancer",[87],"2026-03-25",151,[31],[158],{"trials":1634,"activeCount":12},[],{"trials":1636,"activeCount":12},[],{"trials":1638,"activeCount":12},[],{"intervention":179,"totalTrials":27,"cells":1640},{"EARLY_PHASE1":1641,"PHASE1":1643,"PHASE2":1645,"PHASE3":1655,"PHASE4":1657,"NA":1659},{"trials":1642,"activeCount":12},[],{"trials":1644,"activeCount":12},[],{"trials":1646,"activeCount":27,"soonestReadout":73},[1647,1651],{"nctId":169,"briefTitle":170,"status":147,"phases":1648,"primaryCompletion":172,"completion":172,"start":173,"enrollment":174,"conditions":1649,"interventions":1650},[86,87],[176],[78,178,179,121,180,181,182],{"nctId":76,"briefTitle":77,"status":147,"phases":1652,"primaryCompletion":73,"completion":218,"start":173,"enrollment":219,"conditions":1653,"interventions":1654},[86,87],[15],[78,222,179,121,143,223,224,140,225],{"trials":1656,"activeCount":12},[],{"trials":1658,"activeCount":12},[],{"trials":1660,"activeCount":12},[],{"intervention":49,"totalTrials":94,"cells":1662},{"EARLY_PHASE1":1663,"PHASE1":1665,"PHASE2":1667,"PHASE3":1675,"PHASE4":1677,"NA":1679},{"trials":1664,"activeCount":12},[],{"trials":1666,"activeCount":12},[],{"trials":1668,"activeCount":94,"soonestReadout":48},[1669],{"nctId":46,"briefTitle":47,"status":133,"phases":1670,"primaryCompletion":48,"completion":82,"start":1671,"enrollment":1672,"conditions":1673,"interventions":1674},[86,87],"2022-12-30",220,[18],[49],{"trials":1676,"activeCount":12},[],{"trials":1678,"activeCount":12},[],{"trials":1680,"activeCount":12},[],{"intervention":69,"totalTrials":94,"cells":1682},{"EARLY_PHASE1":1683,"PHASE1":1685,"PHASE2":1687,"PHASE3":1697,"PHASE4":1699,"NA":1701},{"trials":1684,"activeCount":12},[],{"trials":1686,"activeCount":12},[],{"trials":1688,"activeCount":94,"soonestReadout":68},[1689],{"nctId":66,"briefTitle":67,"status":133,"phases":1690,"primaryCompletion":68,"completion":68,"start":1691,"enrollment":1692,"conditions":1693,"interventions":1695},[87],"2024-03-11",153,[1694],"Advanced Gastric Adenocarcinoma and Esophageal Squamous Cell Carcinoma",[69,1696],"Adebrelimab;Oxaliplatin;Capecitabine Tablets;Paclitaxel Injection;Cisplatin",{"trials":1698,"activeCount":12},[],{"trials":1700,"activeCount":12},[],{"trials":1702,"activeCount":12},[],{"intervention":1696,"totalTrials":94,"cells":1704},{"EARLY_PHASE1":1705,"PHASE1":1707,"PHASE2":1709,"PHASE3":1715,"PHASE4":1717,"NA":1719},{"trials":1706,"activeCount":12},[],{"trials":1708,"activeCount":12},[],{"trials":1710,"activeCount":94,"soonestReadout":68},[1711],{"nctId":66,"briefTitle":67,"status":133,"phases":1712,"primaryCompletion":68,"completion":68,"start":1691,"enrollment":1692,"conditions":1713,"interventions":1714},[87],[1694],[69,1696],{"trials":1716,"activeCount":12},[],{"trials":1718,"activeCount":12},[],{"trials":1720,"activeCount":12},[],{"intervention":44,"totalTrials":94,"cells":1722},{"EARLY_PHASE1":1723,"PHASE1":1725,"PHASE2":1727,"PHASE3":1737,"PHASE4":1739,"NA":1741},{"trials":1724,"activeCount":12},[],{"trials":1726,"activeCount":12},[],{"trials":1728,"activeCount":94,"soonestReadout":43},[1729],{"nctId":41,"briefTitle":42,"status":147,"phases":1730,"primaryCompletion":43,"completion":1731,"start":1732,"enrollment":1733,"conditions":1734,"interventions":1736},[87],"2026-10-31","2022-07-05",73,[1735],"Locally Advanced Rectal Cancer",[44],{"trials":1738,"activeCount":12},[],{"trials":1740,"activeCount":12},[],{"trials":1742,"activeCount":12},[],{"intervention":142,"totalTrials":94,"cells":1744},{"EARLY_PHASE1":1745,"PHASE1":1747,"PHASE2":1749,"PHASE3":1755,"PHASE4":1757,"NA":1759},{"trials":1746,"activeCount":12},[],{"trials":1748,"activeCount":12},[],{"trials":1750,"activeCount":94,"soonestReadout":135},[1751],{"nctId":131,"briefTitle":132,"status":133,"phases":1752,"primaryCompletion":135,"completion":135,"start":136,"enrollment":137,"conditions":1753,"interventions":1754},[87],[31],[121,140,141,142,143],{"trials":1756,"activeCount":12},[],{"trials":1758,"activeCount":12},[],{"trials":1760,"activeCount":12},[],{"intervention":1762,"totalTrials":94,"cells":1763},"SHR-4849、SHR-1316、SHR-8068、BP102、carboplatin、cisplatin",{"EARLY_PHASE1":1764,"PHASE1":1766,"PHASE2":1768,"PHASE3":1778,"PHASE4":1780,"NA":1782},{"trials":1765,"activeCount":12},[],{"trials":1767,"activeCount":12},[],{"trials":1769,"activeCount":94,"soonestReadout":513},[1770],{"nctId":1771,"briefTitle":1772,"status":147,"phases":1773,"primaryCompletion":513,"completion":513,"start":1774,"enrollment":1775,"conditions":1776,"interventions":1777},"NCT07028281","A Trial of SHR-4849 Combined With Other Antitumor Drugs in Patients With Malignant Solid Tumors",[87],"2025-07-08",120,[21],[1762],{"trials":1779,"activeCount":12},[],{"trials":1781,"activeCount":12},[],{"trials":1783,"activeCount":12},[],{"intervention":180,"totalTrials":94,"cells":1785},{"EARLY_PHASE1":1786,"PHASE1":1788,"PHASE2":1790,"PHASE3":1796,"PHASE4":1798,"NA":1800},{"trials":1787,"activeCount":12},[],{"trials":1789,"activeCount":12},[],{"trials":1791,"activeCount":94,"soonestReadout":172},[1792],{"nctId":169,"briefTitle":170,"status":147,"phases":1793,"primaryCompletion":172,"completion":172,"start":173,"enrollment":174,"conditions":1794,"interventions":1795},[86,87],[176],[78,178,179,121,180,181,182],{"trials":1797,"activeCount":12},[],{"trials":1799,"activeCount":12},[],{"trials":1801,"activeCount":12},[],{"intervention":181,"totalTrials":94,"cells":1803},{"EARLY_PHASE1":1804,"PHASE1":1806,"PHASE2":1808,"PHASE3":1814,"PHASE4":1816,"NA":1818},{"trials":1805,"activeCount":12},[],{"trials":1807,"activeCount":12},[],{"trials":1809,"activeCount":94,"soonestReadout":172},[1810],{"nctId":169,"briefTitle":170,"status":147,"phases":1811,"primaryCompletion":172,"completion":172,"start":173,"enrollment":174,"conditions":1812,"interventions":1813},[86,87],[176],[78,178,179,121,180,181,182],{"trials":1815,"activeCount":12},[],{"trials":1817,"activeCount":12},[],{"trials":1819,"activeCount":12},[],{"intervention":1821,"totalTrials":94,"cells":1822},"SHR-8068；Adebrelimab",{"EARLY_PHASE1":1823,"PHASE1":1825,"PHASE2":1827,"PHASE3":1839,"PHASE4":1841,"NA":1843},{"trials":1824,"activeCount":12},[],{"trials":1826,"activeCount":12},[],{"trials":1828,"activeCount":94,"soonestReadout":187},[1829],{"nctId":1830,"briefTitle":1831,"status":147,"phases":1832,"primaryCompletion":187,"completion":187,"start":1833,"enrollment":1834,"conditions":1835,"interventions":1836},"NCT05416775","Phase Ib\u002FII Study of SHR-8068 Injection in the Treatment of Advanced Non-small Cell Lung Cancer",[86,87],"2022-08-15",168,[33],[1821,1837,1838],"SHR-8068；adebrelimab and platinum-based chemotherapy","Adebrelimab；platinum-based chemotherapy",{"trials":1840,"activeCount":12},[],{"trials":1842,"activeCount":12},[],{"trials":1844,"activeCount":12},[],{"intervention":1837,"totalTrials":94,"cells":1846},{"EARLY_PHASE1":1847,"PHASE1":1849,"PHASE2":1851,"PHASE3":1857,"PHASE4":1859,"NA":1861},{"trials":1848,"activeCount":12},[],{"trials":1850,"activeCount":12},[],{"trials":1852,"activeCount":94,"soonestReadout":187},[1853],{"nctId":1830,"briefTitle":1831,"status":147,"phases":1854,"primaryCompletion":187,"completion":187,"start":1833,"enrollment":1834,"conditions":1855,"interventions":1856},[86,87],[33],[1821,1837,1838],{"trials":1858,"activeCount":12},[],{"trials":1860,"activeCount":12},[],{"trials":1862,"activeCount":12},[],{"intervention":1838,"totalTrials":94,"cells":1864},{"EARLY_PHASE1":1865,"PHASE1":1867,"PHASE2":1869,"PHASE3":1875,"PHASE4":1877,"NA":1879},{"trials":1866,"activeCount":12},[],{"trials":1868,"activeCount":12},[],{"trials":1870,"activeCount":94,"soonestReadout":187},[1871],{"nctId":1830,"briefTitle":1831,"status":147,"phases":1872,"primaryCompletion":187,"completion":187,"start":1833,"enrollment":1834,"conditions":1873,"interventions":1874},[86,87],[33],[1821,1837,1838],{"trials":1876,"activeCount":12},[],{"trials":1878,"activeCount":12},[],{"trials":1880,"activeCount":12},[],{"intervention":1882,"totalTrials":94,"cells":1883},"SHR-A1811 and SHR-1701",{"EARLY_PHASE1":1884,"PHASE1":1886,"PHASE2":1888,"PHASE3":1906,"PHASE4":1908,"NA":1910},{"trials":1885,"activeCount":12},[],{"trials":1887,"activeCount":12},[],{"trials":1889,"activeCount":94,"soonestReadout":172},[1890],{"nctId":1891,"briefTitle":1892,"status":147,"phases":1893,"primaryCompletion":172,"completion":172,"start":1894,"enrollment":1895,"conditions":1896,"interventions":1898},"NCT05671822","Ph1b\u002F2 Study of the Safety and Efficacy of SHR-A1811 Combinations in Advanced HER2 Expression Gastric Cancer",[87],"2023-03-14",258,[1897],"HER2 Expression Gastric Cancer\u002FGastroesophageal Junction Adenocarcinoma",[1882,1899,1900,1901,1902,1903,1901,1904,1899,1903,1905,1902],"SHR-A1811 and capecitabine","SHR-A181, SHR-1701, and capecitabine","SHR-A1811, SHR-1316, and capecitabine","SHR-A1811, SHR-1316, capecitabine,and oxaliplatin","SHR-A1811, SHR-1316, and 5-FU","SHR-1316 and SHR-A1811","SHR-A1811and 5-FU",{"trials":1907,"activeCount":12},[],{"trials":1909,"activeCount":12},[],{"trials":1911,"activeCount":12},[],{"intervention":1899,"totalTrials":94,"cells":1913},{"EARLY_PHASE1":1914,"PHASE1":1916,"PHASE2":1918,"PHASE3":1924,"PHASE4":1926,"NA":1928},{"trials":1915,"activeCount":12},[],{"trials":1917,"activeCount":12},[],{"trials":1919,"activeCount":94,"soonestReadout":172},[1920],{"nctId":1891,"briefTitle":1892,"status":147,"phases":1921,"primaryCompletion":172,"completion":172,"start":1894,"enrollment":1895,"conditions":1922,"interventions":1923},[87],[1897],[1882,1899,1900,1901,1902,1903,1901,1904,1899,1903,1905,1902],{"trials":1925,"activeCount":12},[],{"trials":1927,"activeCount":12},[],{"trials":1929,"activeCount":12},[],{"intervention":1900,"totalTrials":94,"cells":1931},{"EARLY_PHASE1":1932,"PHASE1":1934,"PHASE2":1936,"PHASE3":1942,"PHASE4":1944,"NA":1946},{"trials":1933,"activeCount":12},[],{"trials":1935,"activeCount":12},[],{"trials":1937,"activeCount":94,"soonestReadout":172},[1938],{"nctId":1891,"briefTitle":1892,"status":147,"phases":1939,"primaryCompletion":172,"completion":172,"start":1894,"enrollment":1895,"conditions":1940,"interventions":1941},[87],[1897],[1882,1899,1900,1901,1902,1903,1901,1904,1899,1903,1905,1902],{"trials":1943,"activeCount":12},[],{"trials":1945,"activeCount":12},[],{"trials":1947,"activeCount":12},[],{"intervention":1901,"totalTrials":94,"cells":1949},{"EARLY_PHASE1":1950,"PHASE1":1952,"PHASE2":1954,"PHASE3":1960,"PHASE4":1962,"NA":1964},{"trials":1951,"activeCount":12},[],{"trials":1953,"activeCount":12},[],{"trials":1955,"activeCount":94,"soonestReadout":172},[1956],{"nctId":1891,"briefTitle":1892,"status":147,"phases":1957,"primaryCompletion":172,"completion":172,"start":1894,"enrollment":1895,"conditions":1958,"interventions":1959},[87],[1897],[1882,1899,1900,1901,1902,1903,1901,1904,1899,1903,1905,1902],{"trials":1961,"activeCount":12},[],{"trials":1963,"activeCount":12},[],{"trials":1965,"activeCount":12},[],{"intervention":1902,"totalTrials":94,"cells":1967},{"EARLY_PHASE1":1968,"PHASE1":1970,"PHASE2":1972,"PHASE3":1978,"PHASE4":1980,"NA":1982},{"trials":1969,"activeCount":12},[],{"trials":1971,"activeCount":12},[],{"trials":1973,"activeCount":94,"soonestReadout":172},[1974],{"nctId":1891,"briefTitle":1892,"status":147,"phases":1975,"primaryCompletion":172,"completion":172,"start":1894,"enrollment":1895,"conditions":1976,"interventions":1977},[87],[1897],[1882,1899,1900,1901,1902,1903,1901,1904,1899,1903,1905,1902],{"trials":1979,"activeCount":12},[],{"trials":1981,"activeCount":12},[],{"trials":1983,"activeCount":12},[],{"intervention":1903,"totalTrials":94,"cells":1985},{"EARLY_PHASE1":1986,"PHASE1":1988,"PHASE2":1990,"PHASE3":1996,"PHASE4":1998,"NA":2000},{"trials":1987,"activeCount":12},[],{"trials":1989,"activeCount":12},[],{"trials":1991,"activeCount":94,"soonestReadout":172},[1992],{"nctId":1891,"briefTitle":1892,"status":147,"phases":1993,"primaryCompletion":172,"completion":172,"start":1894,"enrollment":1895,"conditions":1994,"interventions":1995},[87],[1897],[1882,1899,1900,1901,1902,1903,1901,1904,1899,1903,1905,1902],{"trials":1997,"activeCount":12},[],{"trials":1999,"activeCount":12},[],{"trials":2001,"activeCount":12},[],{"intervention":1904,"totalTrials":94,"cells":2003},{"EARLY_PHASE1":2004,"PHASE1":2006,"PHASE2":2008,"PHASE3":2014,"PHASE4":2016,"NA":2018},{"trials":2005,"activeCount":12},[],{"trials":2007,"activeCount":12},[],{"trials":2009,"activeCount":94,"soonestReadout":172},[2010],{"nctId":1891,"briefTitle":1892,"status":147,"phases":2011,"primaryCompletion":172,"completion":172,"start":1894,"enrollment":1895,"conditions":2012,"interventions":2013},[87],[1897],[1882,1899,1900,1901,1902,1903,1901,1904,1899,1903,1905,1902],{"trials":2015,"activeCount":12},[],{"trials":2017,"activeCount":12},[],{"trials":2019,"activeCount":12},[],{"intervention":1905,"totalTrials":94,"cells":2021},{"EARLY_PHASE1":2022,"PHASE1":2024,"PHASE2":2026,"PHASE3":2032,"PHASE4":2034,"NA":2036},{"trials":2023,"activeCount":12},[],{"trials":2025,"activeCount":12},[],{"trials":2027,"activeCount":94,"soonestReadout":172},[2028],{"nctId":1891,"briefTitle":1892,"status":147,"phases":2029,"primaryCompletion":172,"completion":172,"start":1894,"enrollment":1895,"conditions":2030,"interventions":2031},[87],[1897],[1882,1899,1900,1901,1902,1903,1901,1904,1899,1903,1905,1902],{"trials":2033,"activeCount":12},[],{"trials":2035,"activeCount":12},[],{"trials":2037,"activeCount":12},[],{"intervention":2039,"totalTrials":94,"cells":2040},"SHR-3276",{"EARLY_PHASE1":2041,"PHASE1":2043,"PHASE2":2045,"PHASE3":2057,"PHASE4":2059,"NA":2061},{"trials":2042,"activeCount":12},[],{"trials":2044,"activeCount":12},[],{"trials":2046,"activeCount":94,"soonestReadout":2051},[2047],{"nctId":2048,"briefTitle":2049,"status":147,"phases":2050,"primaryCompletion":2051,"completion":2052,"start":2053,"enrollment":2054,"conditions":2055,"interventions":2056},"NCT06643754","A Clinical Study of SHR-3276 for Injection in Patients With Advanced Malignant Tumors",[86,87],"2027-12-30","2028-12-30","2024-12-10",115,[15],[2039],{"trials":2058,"activeCount":12},[],{"trials":2060,"activeCount":12},[],{"trials":2062,"activeCount":12},[],{"intervention":2064,"totalTrials":94,"cells":2065},"SHR-8068；Adebrelimab ；Bevacizumab",{"EARLY_PHASE1":2066,"PHASE1":2068,"PHASE2":2070,"PHASE3":2083,"PHASE4":2085,"NA":2087},{"trials":2067,"activeCount":12},[],{"trials":2069,"activeCount":12},[],{"trials":2071,"activeCount":94,"soonestReadout":246},[2072],{"nctId":2073,"briefTitle":2074,"status":147,"phases":2075,"primaryCompletion":246,"completion":246,"start":2076,"enrollment":2077,"conditions":2078,"interventions":2080},"NCT07239596","Phase Ib\u002FII Clinical Study of SHR-8068 Combined With Adebrelimab and Other Anti-tumor Drugs in the Treatment of Advanced Renal Cell Carcinom",[86,87],"2026-01-06",139,[2079],"Advanced Renal Cell Carcinoma",[2064,2081,2082],"SHR-8068；Adebrelimab ；HS-10516","SHR-8068； Adebrelimab ； Bevacizumab ；HRS-10516",{"trials":2084,"activeCount":12},[],{"trials":2086,"activeCount":12},[],{"trials":2088,"activeCount":12},[],{"intervention":2081,"totalTrials":94,"cells":2090},{"EARLY_PHASE1":2091,"PHASE1":2093,"PHASE2":2095,"PHASE3":2101,"PHASE4":2103,"NA":2105},{"trials":2092,"activeCount":12},[],{"trials":2094,"activeCount":12},[],{"trials":2096,"activeCount":94,"soonestReadout":246},[2097],{"nctId":2073,"briefTitle":2074,"status":147,"phases":2098,"primaryCompletion":246,"completion":246,"start":2076,"enrollment":2077,"conditions":2099,"interventions":2100},[86,87],[2079],[2064,2081,2082],{"trials":2102,"activeCount":12},[],{"trials":2104,"activeCount":12},[],{"trials":2106,"activeCount":12},[],{"intervention":2082,"totalTrials":94,"cells":2108},{"EARLY_PHASE1":2109,"PHASE1":2111,"PHASE2":2113,"PHASE3":2119,"PHASE4":2121,"NA":2123},{"trials":2110,"activeCount":12},[],{"trials":2112,"activeCount":12},[],{"trials":2114,"activeCount":94,"soonestReadout":246},[2115],{"nctId":2073,"briefTitle":2074,"status":147,"phases":2116,"primaryCompletion":246,"completion":246,"start":2076,"enrollment":2077,"conditions":2117,"interventions":2118},[86,87],[2079],[2064,2081,2082],{"trials":2120,"activeCount":12},[],{"trials":2122,"activeCount":12},[],{"trials":2124,"activeCount":12},[],{"intervention":2126,"totalTrials":94,"cells":2127},"SHR-1681",{"EARLY_PHASE1":2128,"PHASE1":2130,"PHASE2":2132,"PHASE3":2144,"PHASE4":2146,"NA":2148},{"trials":2129,"activeCount":12},[],{"trials":2131,"activeCount":12},[],{"trials":2133,"activeCount":94,"soonestReadout":2138},[2134],{"nctId":2135,"briefTitle":2136,"status":147,"phases":2137,"primaryCompletion":2138,"completion":2139,"start":2140,"enrollment":2141,"conditions":2142,"interventions":2143},"NCT06737731","A Phase I\u002FII Clinical Study of SHR-1681 for Injection in Patients With Advanced Solid Tumors",[86,87],"2026-11","2027-07","2025-01-21",300,[21],[2126],{"trials":2145,"activeCount":12},[],{"trials":2147,"activeCount":12},[],{"trials":2149,"activeCount":12},[],{"intervention":204,"totalTrials":94,"cells":2151},{"EARLY_PHASE1":2152,"PHASE1":2154,"PHASE2":2156,"PHASE3":2162,"PHASE4":2164,"NA":2166},{"trials":2153,"activeCount":12},[],{"trials":2155,"activeCount":12},[],{"trials":2157,"activeCount":94,"soonestReadout":197},[2158],{"nctId":194,"briefTitle":195,"status":147,"phases":2159,"primaryCompletion":197,"completion":198,"start":199,"enrollment":200,"conditions":2160,"interventions":2161},[86,87],[202],[83,204,143,121,141,182],{"trials":2163,"activeCount":12},[],{"trials":2165,"activeCount":12},[],{"trials":2167,"activeCount":12},[],{"intervention":2169,"totalTrials":94,"cells":2170},"SHR-4298",{"EARLY_PHASE1":2171,"PHASE1":2173,"PHASE2":2175,"PHASE3":2185,"PHASE4":2187,"NA":2189},{"trials":2172,"activeCount":12},[],{"trials":2174,"activeCount":12},[],{"trials":2176,"activeCount":94,"soonestReadout":2181},[2177],{"nctId":2178,"briefTitle":2179,"status":109,"phases":2180,"primaryCompletion":2181,"completion":2181,"start":2182,"enrollment":152,"conditions":2183,"interventions":2184},"NCT07229612","A Phase I\u002FII Clinical Study of SHR-4298 Injection in Patients With Malignant Solid Tumors",[86,87],"2028-11","2025-11",[21],[2169],{"trials":2186,"activeCount":12},[],{"trials":2188,"activeCount":12},[],{"trials":2190,"activeCount":12},[],{"intervention":64,"totalTrials":94,"cells":2192},{"EARLY_PHASE1":2193,"PHASE1":2195,"PHASE2":2197,"PHASE3":2207,"PHASE4":2209,"NA":2211},{"trials":2194,"activeCount":12},[],{"trials":2196,"activeCount":12},[],{"trials":2198,"activeCount":94,"soonestReadout":63},[2199],{"nctId":61,"briefTitle":62,"status":147,"phases":2200,"primaryCompletion":63,"completion":150,"start":2201,"enrollment":2202,"conditions":2203,"interventions":2205},[87],"2025-06-24",210,[2204],"For Prevention of Bone Events in Patients With Bone Metastases From Solid Tumors",[64,64,2206],"Denosumab；SHR-2017 placebo",{"trials":2208,"activeCount":12},[],{"trials":2210,"activeCount":12},[],{"trials":2212,"activeCount":12},[],{"intervention":2206,"totalTrials":94,"cells":2214},{"EARLY_PHASE1":2215,"PHASE1":2217,"PHASE2":2219,"PHASE3":2225,"PHASE4":2227,"NA":2229},{"trials":2216,"activeCount":12},[],{"trials":2218,"activeCount":12},[],{"trials":2220,"activeCount":94,"soonestReadout":63},[2221],{"nctId":61,"briefTitle":62,"status":147,"phases":2222,"primaryCompletion":63,"completion":150,"start":2201,"enrollment":2202,"conditions":2223,"interventions":2224},[87],[2204],[64,64,2206],{"trials":2226,"activeCount":12},[],{"trials":2228,"activeCount":12},[],{"trials":2230,"activeCount":12},[],{"intervention":2232,"totalTrials":94,"cells":2233},"SHR-9839(sc) For",{"EARLY_PHASE1":2234,"PHASE1":2236,"PHASE2":2238,"PHASE3":2249,"PHASE4":2251,"NA":2253},{"trials":2235,"activeCount":12},[],{"trials":2237,"activeCount":12},[],{"trials":2239,"activeCount":94,"soonestReadout":2244},[2240],{"nctId":2241,"briefTitle":2242,"status":147,"phases":2243,"primaryCompletion":2244,"completion":712,"start":2245,"enrollment":2246,"conditions":2247,"interventions":2248},"NCT07229638","A IB\u002FII Phase Clinical Study on the Safety, Tolerability, and Efficacy of SHR-9839(sc) in Combination Anti-tumor Therapy in Patients With Solid Tumors",[86,87],"2027-04","2026-02-27",70,[716],[2232],{"trials":2250,"activeCount":12},[],{"trials":2252,"activeCount":12},[],{"trials":2254,"activeCount":12},[],{"intervention":2256,"totalTrials":94,"cells":2257},"Almonertinib combined with SHR-1701",{"EARLY_PHASE1":2258,"PHASE1":2260,"PHASE2":2262,"PHASE3":2275,"PHASE4":2277,"NA":2279},{"trials":2259,"activeCount":12},[],{"trials":2261,"activeCount":12},[],{"trials":2263,"activeCount":94,"soonestReadout":2268},[2264],{"nctId":2265,"briefTitle":2266,"status":109,"phases":2267,"primaryCompletion":2268,"completion":2268,"start":2269,"enrollment":2270,"conditions":2271,"interventions":2273},"NCT05503888","Phase Ib\u002FII Study of Almonertinib Combined With SHR-1701 in the Treatment of Relapsed or Advanced Non-small Cell Lung Cancer",[86,87],"2027-07-30","2022-10-01",160,[2272],"Relapsed or Advanced Non-small Cell Lung Cancer",[2256,2274],"Almonertinib",{"trials":2276,"activeCount":12},[],{"trials":2278,"activeCount":12},[],{"trials":2280,"activeCount":12},[],{"intervention":2274,"totalTrials":94,"cells":2282},{"EARLY_PHASE1":2283,"PHASE1":2285,"PHASE2":2287,"PHASE3":2293,"PHASE4":2295,"NA":2297},{"trials":2284,"activeCount":12},[],{"trials":2286,"activeCount":12},[],{"trials":2288,"activeCount":94,"soonestReadout":2268},[2289],{"nctId":2265,"briefTitle":2266,"status":109,"phases":2290,"primaryCompletion":2268,"completion":2268,"start":2269,"enrollment":2270,"conditions":2291,"interventions":2292},[86,87],[2272],[2256,2274],{"trials":2294,"activeCount":12},[],{"trials":2296,"activeCount":12},[],{"trials":2298,"activeCount":12},[],{"intervention":292,"totalTrials":94,"cells":2300},{"EARLY_PHASE1":2301,"PHASE1":2303,"PHASE2":2305,"PHASE3":2311,"PHASE4":2313,"NA":2315},{"trials":2302,"activeCount":12},[],{"trials":2304,"activeCount":12},[],{"trials":2306,"activeCount":94,"soonestReadout":285},[2307],{"nctId":282,"briefTitle":283,"status":147,"phases":2308,"primaryCompletion":285,"completion":286,"start":287,"enrollment":288,"conditions":2309,"interventions":2310},[86,87],[290],[292,140,293],{"trials":2312,"activeCount":12},[],{"trials":2314,"activeCount":12},[],{"trials":2316,"activeCount":12},[],{"intervention":293,"totalTrials":94,"cells":2318},{"EARLY_PHASE1":2319,"PHASE1":2321,"PHASE2":2323,"PHASE3":2329,"PHASE4":2331,"NA":2333},{"trials":2320,"activeCount":12},[],{"trials":2322,"activeCount":12},[],{"trials":2324,"activeCount":94,"soonestReadout":285},[2325],{"nctId":282,"briefTitle":283,"status":147,"phases":2326,"primaryCompletion":285,"completion":286,"start":287,"enrollment":288,"conditions":2327,"interventions":2328},[86,87],[290],[292,140,293],{"trials":2330,"activeCount":12},[],{"trials":2332,"activeCount":12},[],{"trials":2334,"activeCount":12},[],{"intervention":2336,"totalTrials":94,"cells":2337},"SHR-1826；Adebrelimab；SHR-8068；Bevacizumab",{"EARLY_PHASE1":2338,"PHASE1":2340,"PHASE2":2342,"PHASE3":2354,"PHASE4":2356,"NA":2358},{"trials":2339,"activeCount":12},[],{"trials":2341,"activeCount":12},[],{"trials":2343,"activeCount":94,"soonestReadout":2348},[2344],{"nctId":2345,"briefTitle":2346,"status":147,"phases":2347,"primaryCompletion":2348,"completion":2349,"start":2350,"enrollment":2141,"conditions":2351,"interventions":2353},"NCT06844474","A Phase II Clinical Study of SHR-1826 for Injection in Patients With NSCLC",[87],"2026-08-31","2028-02-29","2025-03-07",[2352],"NSCLC",[2336],{"trials":2355,"activeCount":12},[],{"trials":2357,"activeCount":12},[],{"trials":2359,"activeCount":12},[],{"intervention":311,"totalTrials":94,"cells":2361},{"EARLY_PHASE1":2362,"PHASE1":2364,"PHASE2":2366,"PHASE3":2372,"PHASE4":2374,"NA":2376},{"trials":2363,"activeCount":12},[],{"trials":2365,"activeCount":12},[],{"trials":2367,"activeCount":94,"soonestReadout":305},[2368],{"nctId":302,"briefTitle":303,"status":147,"phases":2369,"primaryCompletion":305,"completion":306,"start":307,"enrollment":308,"conditions":2370,"interventions":2371},[86,87],[24],[83,182,143,311,312,313,140],{"trials":2373,"activeCount":12},[],{"trials":2375,"activeCount":12},[],{"trials":2377,"activeCount":12},[],{"intervention":313,"totalTrials":94,"cells":2379},{"EARLY_PHASE1":2380,"PHASE1":2382,"PHASE2":2384,"PHASE3":2390,"PHASE4":2392,"NA":2394},{"trials":2381,"activeCount":12},[],{"trials":2383,"activeCount":12},[],{"trials":2385,"activeCount":94,"soonestReadout":305},[2386],{"nctId":302,"briefTitle":303,"status":147,"phases":2387,"primaryCompletion":305,"completion":306,"start":307,"enrollment":308,"conditions":2388,"interventions":2389},[86,87],[24],[83,182,143,311,312,313,140],{"trials":2391,"activeCount":12},[],{"trials":2393,"activeCount":12},[],{"trials":2395,"activeCount":12},[],{"intervention":222,"totalTrials":94,"cells":2397},{"EARLY_PHASE1":2398,"PHASE1":2400,"PHASE2":2402,"PHASE3":2408,"PHASE4":2410,"NA":2412},{"trials":2399,"activeCount":12},[],{"trials":2401,"activeCount":12},[],{"trials":2403,"activeCount":94,"soonestReadout":73},[2404],{"nctId":76,"briefTitle":77,"status":147,"phases":2405,"primaryCompletion":73,"completion":218,"start":173,"enrollment":219,"conditions":2406,"interventions":2407},[86,87],[15],[78,222,179,121,143,223,224,140,225],{"trials":2409,"activeCount":12},[],{"trials":2411,"activeCount":12},[],{"trials":2413,"activeCount":12},[],{"intervention":223,"totalTrials":94,"cells":2415},{"EARLY_PHASE1":2416,"PHASE1":2418,"PHASE2":2420,"PHASE3":2426,"PHASE4":2428,"NA":2430},{"trials":2417,"activeCount":12},[],{"trials":2419,"activeCount":12},[],{"trials":2421,"activeCount":94,"soonestReadout":73},[2422],{"nctId":76,"briefTitle":77,"status":147,"phases":2423,"primaryCompletion":73,"completion":218,"start":173,"enrollment":219,"conditions":2424,"interventions":2425},[86,87],[15],[78,222,179,121,143,223,224,140,225],{"trials":2427,"activeCount":12},[],{"trials":2429,"activeCount":12},[],{"trials":2431,"activeCount":12},[],{"intervention":224,"totalTrials":94,"cells":2433},{"EARLY_PHASE1":2434,"PHASE1":2436,"PHASE2":2438,"PHASE3":2444,"PHASE4":2446,"NA":2448},{"trials":2435,"activeCount":12},[],{"trials":2437,"activeCount":12},[],{"trials":2439,"activeCount":94,"soonestReadout":73},[2440],{"nctId":76,"briefTitle":77,"status":147,"phases":2441,"primaryCompletion":73,"completion":218,"start":173,"enrollment":219,"conditions":2442,"interventions":2443},[86,87],[15],[78,222,179,121,143,223,224,140,225],{"trials":2445,"activeCount":12},[],{"trials":2447,"activeCount":12},[],{"trials":2449,"activeCount":12},[],{"intervention":225,"totalTrials":94,"cells":2451},{"EARLY_PHASE1":2452,"PHASE1":2454,"PHASE2":2456,"PHASE3":2462,"PHASE4":2464,"NA":2466},{"trials":2453,"activeCount":12},[],{"trials":2455,"activeCount":12},[],{"trials":2457,"activeCount":94,"soonestReadout":73},[2458],{"nctId":76,"briefTitle":77,"status":147,"phases":2459,"primaryCompletion":73,"completion":218,"start":173,"enrollment":219,"conditions":2460,"interventions":2461},[86,87],[15],[78,222,179,121,143,223,224,140,225],{"trials":2463,"activeCount":12},[],{"trials":2465,"activeCount":12},[],{"trials":2467,"activeCount":12},[],{"intervention":54,"totalTrials":94,"cells":2469},{"EARLY_PHASE1":2470,"PHASE1":2472,"PHASE2":2481,"PHASE3":2483,"PHASE4":2485,"NA":2487},{"trials":2471,"activeCount":12},[],{"trials":2473,"activeCount":94,"soonestReadout":53},[2474],{"nctId":51,"briefTitle":52,"status":147,"phases":2475,"primaryCompletion":53,"completion":2476,"start":2477,"enrollment":2478,"conditions":2479,"interventions":2480},[86],"2026-05-30","2023-04-18",133,[18],[54],{"trials":2482,"activeCount":12},[],{"trials":2484,"activeCount":12},[],{"trials":2486,"activeCount":12},[],{"trials":2488,"activeCount":12},[],{"intervention":348,"totalTrials":94,"cells":2490},{"EARLY_PHASE1":2491,"PHASE1":2493,"PHASE2":2499,"PHASE3":2501,"PHASE4":2503,"NA":2505},{"trials":2492,"activeCount":12},[],{"trials":2494,"activeCount":94,"soonestReadout":342},[2495],{"nctId":339,"briefTitle":340,"status":147,"phases":2496,"primaryCompletion":342,"completion":172,"start":343,"enrollment":344,"conditions":2497,"interventions":2498},[86],[346],[348,143],{"trials":2500,"activeCount":12},[],{"trials":2502,"activeCount":12},[],{"trials":2504,"activeCount":12},[],{"trials":2506,"activeCount":12},[],{"intervention":2508,"totalTrials":94,"cells":2509},"SHR-7782",{"EARLY_PHASE1":2510,"PHASE1":2512,"PHASE2":2521,"PHASE3":2523,"PHASE4":2525,"NA":2527},{"trials":2511,"activeCount":12},[],{"trials":2513,"activeCount":94,"soonestReadout":1136},[2514],{"nctId":2515,"briefTitle":2516,"status":147,"phases":2517,"primaryCompletion":1136,"completion":172,"start":151,"enrollment":152,"conditions":2518,"interventions":2520},"NCT07123129","A Trial of SHR-7782 for Treatment of Advanced Malignant Tumors",[86],[2519],"Advanced Malignancy",[2508],{"trials":2522,"activeCount":12},[],{"trials":2524,"activeCount":12},[],{"trials":2526,"activeCount":12},[],{"trials":2528,"activeCount":12},[],{"intervention":2530,"totalTrials":94,"cells":2531},"SHR-2022",{"EARLY_PHASE1":2532,"PHASE1":2534,"PHASE2":2545,"PHASE3":2547,"PHASE4":2549,"NA":2551},{"trials":2533,"activeCount":12},[],{"trials":2535,"activeCount":94,"soonestReadout":1136},[2536],{"nctId":2537,"briefTitle":2538,"status":109,"phases":2539,"primaryCompletion":1136,"completion":1136,"start":2540,"enrollment":2541,"conditions":2542,"interventions":2544},"NCT06131216","Phase I Study of SHR-2022 Injection in the Treatment of Patients With Advanced Malignant Tumors",[86],"2023-12",116,[2543],"Advanced Malignant Cancer",[2530],{"trials":2546,"activeCount":12},[],{"trials":2548,"activeCount":12},[],{"trials":2550,"activeCount":12},[],{"trials":2552,"activeCount":12},[],{"intervention":2554,"totalTrials":94,"cells":2555},"SHR-1894",{"EARLY_PHASE1":2556,"PHASE1":2558,"PHASE2":2570,"PHASE3":2572,"PHASE4":2574,"NA":2576},{"trials":2557,"activeCount":12},[],{"trials":2559,"activeCount":94,"soonestReadout":197},[2560],{"nctId":2561,"briefTitle":2562,"status":147,"phases":2563,"primaryCompletion":197,"completion":1136,"start":2564,"enrollment":2565,"conditions":2566,"interventions":2568},"NCT07414602","A Phase I Study of Single Subcutaneous Dose of SHR-1894 in Healthy Subjects",[86],"2026-03-16",40,[2567],"Dermatitis",[2554,2569],"SHR-1894 Injection Placebo",{"trials":2571,"activeCount":12},[],{"trials":2573,"activeCount":12},[],{"trials":2575,"activeCount":12},[],{"trials":2577,"activeCount":12},[],{"intervention":2569,"totalTrials":94,"cells":2579},{"EARLY_PHASE1":2580,"PHASE1":2582,"PHASE2":2588,"PHASE3":2590,"PHASE4":2592,"NA":2594},{"trials":2581,"activeCount":12},[],{"trials":2583,"activeCount":94,"soonestReadout":197},[2584],{"nctId":2561,"briefTitle":2562,"status":147,"phases":2585,"primaryCompletion":197,"completion":1136,"start":2564,"enrollment":2565,"conditions":2586,"interventions":2587},[86],[2567],[2554,2569],{"trials":2589,"activeCount":12},[],{"trials":2591,"activeCount":12},[],{"trials":2593,"activeCount":12},[],{"trials":2595,"activeCount":12},[],{"intervention":74,"totalTrials":94,"cells":2597},{"EARLY_PHASE1":2598,"PHASE1":2600,"PHASE2":2609,"PHASE3":2611,"PHASE4":2613,"NA":2615},{"trials":2599,"activeCount":12},[],{"trials":2601,"activeCount":94,"soonestReadout":73},[2602],{"nctId":71,"briefTitle":72,"status":147,"phases":2603,"primaryCompletion":73,"completion":2604,"start":2605,"enrollment":2606,"conditions":2607,"interventions":2608},[86],"2027-01-01","2024-11-13",162,[15],[74],{"trials":2610,"activeCount":12},[],{"trials":2612,"activeCount":12},[],{"trials":2614,"activeCount":12},[],{"trials":2616,"activeCount":12},[],{"intervention":718,"totalTrials":94,"cells":2618},{"EARLY_PHASE1":2619,"PHASE1":2621,"PHASE2":2627,"PHASE3":2629,"PHASE4":2631,"NA":2633},{"trials":2620,"activeCount":12},[],{"trials":2622,"activeCount":94,"soonestReadout":712},[2623],{"nctId":709,"briefTitle":710,"status":147,"phases":2624,"primaryCompletion":712,"completion":172,"start":713,"enrollment":714,"conditions":2625,"interventions":2626},[86],[716],[718,157],{"trials":2628,"activeCount":12},[],{"trials":2630,"activeCount":12},[],{"trials":2632,"activeCount":12},[],{"trials":2634,"activeCount":12},[],{"intervention":2636,"totalTrials":94,"cells":2637},"SHR-3792",{"EARLY_PHASE1":2638,"PHASE1":2640,"PHASE2":2650,"PHASE3":2652,"PHASE4":2654,"NA":2656},{"trials":2639,"activeCount":12},[],{"trials":2641,"activeCount":94,"soonestReadout":2646},[2642],{"nctId":2643,"briefTitle":2644,"status":147,"phases":2645,"primaryCompletion":2646,"completion":2646,"start":2647,"enrollment":308,"conditions":2648,"interventions":2649},"NCT06907628","A Trial of SHR-3792 Injection in Patients With Advanced Solid Tumors",[86],"2027-02","2025-04-02",[15],[2636],{"trials":2651,"activeCount":12},[],{"trials":2653,"activeCount":12},[],{"trials":2655,"activeCount":12},[],{"trials":2657,"activeCount":12},[],{"intervention":2659,"totalTrials":94,"cells":2660},"SHR-4849",{"EARLY_PHASE1":2661,"PHASE1":2663,"PHASE2":2673,"PHASE3":2675,"PHASE4":2677,"NA":2679},{"trials":2662,"activeCount":12},[],{"trials":2664,"activeCount":94,"soonestReadout":1136},[2665],{"nctId":2666,"briefTitle":2667,"status":147,"phases":2668,"primaryCompletion":1136,"completion":1136,"start":2669,"enrollment":2670,"conditions":2671,"interventions":2672},"NCT06443489","A Trial of SHR-4849 in Advanced Solid Tumors",[86],"2024-06-26",80,[15],[2659],{"trials":2674,"activeCount":12},[],{"trials":2676,"activeCount":12},[],{"trials":2678,"activeCount":12},[],{"trials":2680,"activeCount":12},[],{"intervention":454,"totalTrials":94,"cells":2682},{"EARLY_PHASE1":2683,"PHASE1":2685,"PHASE2":2691,"PHASE3":2693,"PHASE4":2695,"NA":2697},{"trials":2684,"activeCount":12},[],{"trials":2686,"activeCount":94,"soonestReadout":58},[2687],{"nctId":56,"briefTitle":57,"status":147,"phases":2688,"primaryCompletion":58,"completion":210,"start":449,"enrollment":450,"conditions":2689,"interventions":2690},[86],[452],[59,178,182,454],{"trials":2692,"activeCount":12},[],{"trials":2694,"activeCount":12},[],{"trials":2696,"activeCount":12},[],{"trials":2698,"activeCount":12},[],{"intervention":2700,"totalTrials":94,"cells":2701},"SHR-4506",{"EARLY_PHASE1":2702,"PHASE1":2704,"PHASE2":2715,"PHASE3":2717,"PHASE4":2719,"NA":2721},{"trials":2703,"activeCount":12},[],{"trials":2705,"activeCount":94,"soonestReadout":2646},[2706],{"nctId":2707,"briefTitle":2708,"status":147,"phases":2709,"primaryCompletion":2646,"completion":2710,"start":164,"enrollment":2711,"conditions":2712,"interventions":2714},"NCT07068932","A Clinical Study of SHR-4506 Injection in Patients With Malignant Tumors",[86],"2027-08",102,[2713],"Malignant Tumors of Adults",[2700],{"trials":2716,"activeCount":12},[],{"trials":2718,"activeCount":12},[],{"trials":2720,"activeCount":12},[],{"trials":2722,"activeCount":12},[],{"intervention":2724,"totalTrials":94,"cells":2725},"SHR-9539 for",{"EARLY_PHASE1":2726,"PHASE1":2728,"PHASE2":2739,"PHASE3":2741,"PHASE4":2743,"NA":2745},{"trials":2727,"activeCount":12},[],{"trials":2729,"activeCount":94,"soonestReadout":1551},[2730],{"nctId":2731,"briefTitle":2732,"status":147,"phases":2733,"primaryCompletion":1551,"completion":1551,"start":2734,"enrollment":2735,"conditions":2736,"interventions":2738},"NCT06484777","A Clinical Study of SHR-9539 in Patients With Multiple Myeloma",[86],"2024-08-07",138,[2737],"Multiple Myeloma",[2724],{"trials":2740,"activeCount":12},[],{"trials":2742,"activeCount":12},[],{"trials":2744,"activeCount":12},[],{"trials":2746,"activeCount":12},[],{"intervention":2748,"totalTrials":94,"cells":2749},"SHR-1701",{"EARLY_PHASE1":2750,"PHASE1":2752,"PHASE2":2754,"PHASE3":2756,"PHASE4":2768,"NA":2770},{"trials":2751,"activeCount":12},[],{"trials":2753,"activeCount":12},[],{"trials":2755,"activeCount":12},[],{"trials":2757,"activeCount":12},[2758],{"nctId":2759,"briefTitle":2760,"status":615,"phases":2761,"primaryCompletion":2762,"completion":2762,"start":2763,"enrollment":2764,"conditions":2765,"interventions":2767},"NCT05149807","Clinical Study of SHR-1701 Plus Chemotherapy as Perioperative Treatment in Subjects With Gastric Cancer",[87,88],"2024-04-03","2022-01-26",81,[2766],"Perioperative Treatment in Subjects With Locally Advanced Resectable Gastric Cancer or Gastroesophageal Junction Cancer",[2748],{"trials":2769,"activeCount":12},[],{"trials":2771,"activeCount":12},[],{"intervention":2773,"totalTrials":94,"cells":2774},"SHR-1701、 BP102 、XELOX",{"EARLY_PHASE1":2775,"PHASE1":2777,"PHASE2":2779,"PHASE3":2781,"PHASE4":2793,"NA":2795},{"trials":2776,"activeCount":12},[],{"trials":2778,"activeCount":12},[],{"trials":2780,"activeCount":12},[],{"trials":2782,"activeCount":12},[2783],{"nctId":2784,"briefTitle":2785,"status":615,"phases":2786,"primaryCompletion":2787,"completion":2787,"start":2788,"enrollment":2789,"conditions":2790,"interventions":2792},"NCT04856787","A Clinical Studyf of SHR-1701 or Placebo in Combination With BP102 and XELOX in the First-line Treatment of mCRC",[87,88],"2024-04-17","2021-06-22",62,[2791],"Metastatic Colorectal Cancer (mCRC)",[2773,2773],{"trials":2794,"activeCount":12},[],{"trials":2796,"activeCount":12},[],{"intervention":2798,"totalTrials":94,"cells":2799},"SHR-1701 + Pemetrexed Disodium + cisplatin\u002Fcarboplatin + bevacizumab",{"EARLY_PHASE1":2800,"PHASE1":2802,"PHASE2":2804,"PHASE3":2806,"PHASE4":2818,"NA":2820},{"trials":2801,"activeCount":12},[],{"trials":2803,"activeCount":12},[],{"trials":2805,"activeCount":12},[],{"trials":2807,"activeCount":12},[2808],{"nctId":2809,"briefTitle":2810,"status":397,"phases":2811,"primaryCompletion":2812,"completion":2812,"start":2813,"enrollment":2814,"conditions":2815,"interventions":2817},"NCT05132413","A Study of SHR-1701 Plus Bevacizumab and Chemotherapy in Non-Small-Cell-Lung-Cancer",[88],"2024-12-30","2021-12-30",561,[2816],"Advanced or Metastatic Non-squamous Non-small-cell Lung Cancer",[2798],{"trials":2819,"activeCount":12},[],{"trials":2821,"activeCount":12},[],{"intervention":2823,"totalTrials":94,"cells":2824},"Camrelizumab、Capecitabine\u002Feribulin\u002Fgemcitabine\u002Fvinorelbine",{"EARLY_PHASE1":2825,"PHASE1":2827,"PHASE2":2829,"PHASE3":2831,"PHASE4":2843,"NA":2845},{"trials":2826,"activeCount":12},[],{"trials":2828,"activeCount":12},[],{"trials":2830,"activeCount":12},[],{"trials":2832,"activeCount":12},[2833],{"nctId":2834,"briefTitle":2835,"status":615,"phases":2836,"primaryCompletion":2837,"completion":2838,"start":2837,"enrollment":94,"conditions":2839,"interventions":2841},"NCT05134194","A Study of Camrelizumab in Combination With Chemotherapy Regimen Comparative Chemotherapy Regimen for Metastatic Triple-negative Breast Cancer",[88],"2022-01-17","2022-12-15",[2840],"Triple Negative Breast Cancer",[2823,2842],"Capecitabine\u002Feribulin\u002Fgemcitabine\u002Fvinorelbine",{"trials":2844,"activeCount":12},[],{"trials":2846,"activeCount":12},[],{"intervention":2842,"totalTrials":94,"cells":2848},{"EARLY_PHASE1":2849,"PHASE1":2851,"PHASE2":2853,"PHASE3":2855,"PHASE4":2861,"NA":2863},{"trials":2850,"activeCount":12},[],{"trials":2852,"activeCount":12},[],{"trials":2854,"activeCount":12},[],{"trials":2856,"activeCount":12},[2857],{"nctId":2834,"briefTitle":2835,"status":615,"phases":2858,"primaryCompletion":2837,"completion":2838,"start":2837,"enrollment":94,"conditions":2859,"interventions":2860},[88],[2840],[2823,2842],{"trials":2862,"activeCount":12},[],{"trials":2864,"activeCount":12},[],{"intervention":2866,"totalTrials":94,"cells":2867},"SHR-1701 + paclitaxel + cisplatin\u002Fcarboplatin + BP102",{"EARLY_PHASE1":2868,"PHASE1":2870,"PHASE2":2872,"PHASE3":2874,"PHASE4":2887,"NA":2889},{"trials":2869,"activeCount":12},[],{"trials":2871,"activeCount":12},[],{"trials":2873,"activeCount":12},[],{"trials":2875,"activeCount":12},[2876],{"nctId":2877,"briefTitle":2878,"status":615,"phases":2879,"primaryCompletion":2880,"completion":2880,"start":2881,"enrollment":2882,"conditions":2883,"interventions":2885},"NCT05179239","A Study of SHR-1701 Plus Platinum-containing Chemotherapy With or Without BP102 (Bevacizumab) as First-line Treatment in Cervical Cancer",[88],"2024-08-12","2022-02-26",31,[2884],"Cervical Cancer",[2866,2886],"SHR-1701 + paclitaxel + cisplatin\u002Fcarboplatin± BP102",{"trials":2888,"activeCount":12},[],{"trials":2890,"activeCount":12},[],{"intervention":2886,"totalTrials":94,"cells":2892},{"EARLY_PHASE1":2893,"PHASE1":2895,"PHASE2":2897,"PHASE3":2899,"PHASE4":2905,"NA":2907},{"trials":2894,"activeCount":12},[],{"trials":2896,"activeCount":12},[],{"trials":2898,"activeCount":12},[],{"trials":2900,"activeCount":12},[2901],{"nctId":2877,"briefTitle":2878,"status":615,"phases":2902,"primaryCompletion":2880,"completion":2880,"start":2881,"enrollment":2882,"conditions":2903,"interventions":2904},[88],[2884],[2866,2886],{"trials":2906,"activeCount":12},[],{"trials":2908,"activeCount":12},[],{"intervention":2910,"totalTrials":27,"cells":2911},"SHR-1701；BP102",{"EARLY_PHASE1":2912,"PHASE1":2914,"PHASE2":2916,"PHASE3":2937,"PHASE4":2939,"NA":2941},{"trials":2913,"activeCount":12},[],{"trials":2915,"activeCount":12},[],{"trials":2917,"activeCount":12},[2918,2926],{"nctId":2919,"briefTitle":2920,"status":593,"phases":2921,"primaryCompletion":2922,"completion":2922,"start":2923,"enrollment":2764,"conditions":2924,"interventions":2925},"NCT04856774","Trial of SHR-1701 Plus BP102 in Subjects With Selected Solid Tumors",[86,87],"2024-03-30","2021-06-01",[15],[2910],{"nctId":2927,"briefTitle":2928,"status":397,"phases":2929,"primaryCompletion":2930,"completion":2931,"start":2932,"enrollment":2933,"conditions":2934,"interventions":2936},"NCT04974957","Study of SHR-1701 Plus BP102 in Subjects With Selected Solid Tumors",[87],"2022-02-28","2022-08-30","2021-08-30",71,[2935],"Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer",[2910],{"trials":2938,"activeCount":12},[],{"trials":2940,"activeCount":12},[],{"trials":2942,"activeCount":12},[],{"intervention":2944,"totalTrials":94,"cells":2945},"SHR-A2009 for injection ； Almonertinib Mesilate",{"EARLY_PHASE1":2946,"PHASE1":2948,"PHASE2":2950,"PHASE3":2961,"PHASE4":2963,"NA":2965},{"trials":2947,"activeCount":12},[],{"trials":2949,"activeCount":12},[],{"trials":2951,"activeCount":12},[2952],{"nctId":2953,"briefTitle":2954,"status":397,"phases":2955,"primaryCompletion":63,"completion":63,"start":2956,"enrollment":2957,"conditions":2958,"interventions":2959},"NCT06092268","A Phase IB\u002FII Clinical Study of SHR-A2009 for Injection in Combination With Other Antitumor Therapies in Patients With Advanced Solid Tumors",[86,87],"2023-10",270,[15],[2944,2960],"SHR-A2009 for injection；Adebrelimab",{"trials":2962,"activeCount":12},[],{"trials":2964,"activeCount":12},[],{"trials":2966,"activeCount":12},[],{"intervention":2960,"totalTrials":94,"cells":2968},{"EARLY_PHASE1":2969,"PHASE1":2971,"PHASE2":2973,"PHASE3":2979,"PHASE4":2981,"NA":2983},{"trials":2970,"activeCount":12},[],{"trials":2972,"activeCount":12},[],{"trials":2974,"activeCount":12},[2975],{"nctId":2953,"briefTitle":2954,"status":397,"phases":2976,"primaryCompletion":63,"completion":63,"start":2956,"enrollment":2957,"conditions":2977,"interventions":2978},[86,87],[15],[2944,2960],{"trials":2980,"activeCount":12},[],{"trials":2982,"activeCount":12},[],{"trials":2984,"activeCount":12},[],{"intervention":2986,"totalTrials":94,"cells":2987},"SHR-A1811 for injection ; capecitabine",{"EARLY_PHASE1":2988,"PHASE1":2990,"PHASE2":2992,"PHASE3":3004,"PHASE4":3006,"NA":3008},{"trials":2989,"activeCount":12},[],{"trials":2991,"activeCount":12},[],{"trials":2993,"activeCount":12},[2994],{"nctId":2995,"briefTitle":2996,"status":397,"phases":2997,"primaryCompletion":2998,"completion":2999,"start":3000,"enrollment":2541,"conditions":3001,"interventions":3003},"NCT05845138","A Study of SHR-A1811 Combined With Capecitabine in Treatment of Unresectable or Metastatic Breast Cancer With Low HER2 Expression.",[86,87],"2024-12-31","2025-12-31","2023-07-25",[3002],"Breast Cancer",[2986],{"trials":3005,"activeCount":12},[],{"trials":3007,"activeCount":12},[],{"trials":3009,"activeCount":12},[],{"intervention":3011,"totalTrials":94,"cells":3012},"SHR-A1921；Adebrelimab；SHR-8068；carboplatin",{"EARLY_PHASE1":3013,"PHASE1":3015,"PHASE2":3017,"PHASE3":3027,"PHASE4":3029,"NA":3031},{"trials":3014,"activeCount":12},[],{"trials":3016,"activeCount":12},[],{"trials":3018,"activeCount":12},[3019],{"nctId":3020,"briefTitle":3021,"status":3022,"phases":3023,"primaryCompletion":3024,"completion":3024,"start":3024,"enrollment":12,"conditions":3025,"interventions":3026},"NCT06434103","Clinical Study of SHR-A1921 Combined With Adebrelimab and SHR-8068 With or Without Carboplatin in the Treatment of Advanced NSCLC","WITHDRAWN",[86,87],"2024-10-10",[33],[3011],{"trials":3028,"activeCount":12},[],{"trials":3030,"activeCount":12},[],{"trials":3032,"activeCount":12},[],{"intervention":405,"totalTrials":94,"cells":3034},{"EARLY_PHASE1":3035,"PHASE1":3037,"PHASE2":3039,"PHASE3":3045,"PHASE4":3047,"NA":3049},{"trials":3036,"activeCount":12},[],{"trials":3038,"activeCount":12},[],{"trials":3040,"activeCount":12},[3041],{"nctId":395,"briefTitle":396,"status":397,"phases":3042,"primaryCompletion":399,"completion":400,"start":401,"enrollment":402,"conditions":3043,"interventions":3044},[87],[15],[83,405],{"trials":3046,"activeCount":12},[],{"trials":3048,"activeCount":12},[],{"trials":3050,"activeCount":12},[],{"intervention":3052,"totalTrials":27,"cells":3053},"SHR-2017",{"EARLY_PHASE1":3054,"PHASE1":3056,"PHASE2":3077,"PHASE3":3079,"PHASE4":3081,"NA":3083},{"trials":3055,"activeCount":12},[],{"trials":3057,"activeCount":12},[3058,3067],{"nctId":3059,"briefTitle":3060,"status":593,"phases":3061,"primaryCompletion":3062,"completion":3062,"start":38,"enrollment":3063,"conditions":3064,"interventions":3066},"NCT06380881","PK\u002FPD Study of SHR-2017 Injection in Patients With Bone Metastases",[86],"2025-08-06",25,[3065],"Patients With Bone Metastases",[3052],{"nctId":3068,"briefTitle":3069,"status":397,"phases":3070,"primaryCompletion":3071,"completion":3071,"start":3072,"enrollment":3073,"conditions":3074,"interventions":3076},"NCT05930704","Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SHR-2017 Injection in Postmenopausal Women",[86],"2025-04-12","2023-07-04",45,[3075],"Osteoporosis",[3052],{"trials":3078,"activeCount":12},[],{"trials":3080,"activeCount":12},[],{"trials":3082,"activeCount":12},[],{"trials":3084,"activeCount":12},[],{"intervention":3086,"totalTrials":27,"cells":3087},"SHR-A2009",{"EARLY_PHASE1":3088,"PHASE1":3090,"PHASE2":3110,"PHASE3":3112,"PHASE4":3114,"NA":3116},{"trials":3089,"activeCount":12},[],{"trials":3091,"activeCount":12},[3092,3101],{"nctId":3093,"briefTitle":3094,"status":593,"phases":3095,"primaryCompletion":3096,"completion":3096,"start":3097,"enrollment":3098,"conditions":3099,"interventions":3100},"NCT05394818","The Clinical Study of SHR-A2009 for Injection in Patients With Advanced Solid Tumors",[86],"2024-04-30","2022-07-21",19,[18],[3086],{"nctId":3102,"briefTitle":3103,"status":397,"phases":3104,"primaryCompletion":3105,"completion":2812,"start":3106,"enrollment":3107,"conditions":3108,"interventions":3109},"NCT05114759","A Phase I Clinical Study of SHR-A2009 for Injection in Patients With Advanced Solid Tumors",[86],"2023-12-30","2022-01-04",132,[15],[3086],{"trials":3111,"activeCount":12},[],{"trials":3113,"activeCount":12},[],{"trials":3115,"activeCount":12},[],{"trials":3117,"activeCount":12},[],{"intervention":3119,"totalTrials":94,"cells":3120},"SHR-1901",{"EARLY_PHASE1":3121,"PHASE1":3123,"PHASE2":3133,"PHASE3":3135,"PHASE4":3137,"NA":3139},{"trials":3122,"activeCount":12},[],{"trials":3124,"activeCount":12},[3125],{"nctId":3126,"briefTitle":3127,"status":397,"phases":3128,"primaryCompletion":3129,"completion":798,"start":3130,"enrollment":3063,"conditions":3131,"interventions":3132},"NCT05193721","A Clinical Study of the Safety and Tolerability of SHR-1901 in Subjects With Advanced Malignant Tumors",[86],"2024-06-30","2022-02-10",[26],[3119],{"trials":3134,"activeCount":12},[],{"trials":3136,"activeCount":12},[],{"trials":3138,"activeCount":12},[],{"trials":3140,"activeCount":12},[],{"intervention":3142,"totalTrials":94,"cells":3143},"SHR-7631",{"EARLY_PHASE1":3144,"PHASE1":3146,"PHASE2":3157,"PHASE3":3159,"PHASE4":3161,"NA":3163},{"trials":3145,"activeCount":12},[],{"trials":3147,"activeCount":12},[3148],{"nctId":3149,"briefTitle":3150,"status":593,"phases":3151,"primaryCompletion":3152,"completion":3152,"start":3153,"enrollment":3154,"conditions":3155,"interventions":3156},"NCT06381050","The Clinical Study of SHR-7631 for Injection in Patients With Advanced Solid Tumors",[86],"2025-03-21","2024-05-24",76,[15],[3142],{"trials":3158,"activeCount":12},[],{"trials":3160,"activeCount":12},[],{"trials":3162,"activeCount":12},[],{"trials":3164,"activeCount":12},[],{"intervention":3166,"totalTrials":94,"cells":3167},"SHR-2002 injection、Camrelizumab for Injection, SHR-1316 injection, SHR-1701",{"EARLY_PHASE1":3168,"PHASE1":3170,"PHASE2":3181,"PHASE3":3183,"PHASE4":3185,"NA":3187},{"trials":3169,"activeCount":12},[],{"trials":3171,"activeCount":12},[3172],{"nctId":3173,"briefTitle":3174,"status":397,"phases":3175,"primaryCompletion":3176,"completion":3177,"start":3178,"enrollment":1553,"conditions":3179,"interventions":3180},"NCT05198817","A Trial of SHR-2002 Injection or Combined With Other Anti-cancer Medication in Advanced Malignant Tumors of Patients",[86],"2023-01-31","2023-06-30","2022-02-22",[26],[3166],{"trials":3182,"activeCount":12},[],{"trials":3184,"activeCount":12},[],{"trials":3186,"activeCount":12},[],{"trials":3188,"activeCount":12},[],{"intervention":3190,"totalTrials":94,"cells":3191},"SHR-5495 for",{"EARLY_PHASE1":3192,"PHASE1":3194,"PHASE2":3204,"PHASE3":3206,"PHASE4":3208,"NA":3210},{"trials":3193,"activeCount":12},[],{"trials":3195,"activeCount":12},[3196],{"nctId":3197,"briefTitle":3198,"status":397,"phases":3199,"primaryCompletion":2999,"completion":2999,"start":3200,"enrollment":200,"conditions":3201,"interventions":3203},"NCT06059508","Phase I Clinical Study of SHR-5495 in the Treatment of Patients With Advanced Malignant Tumors",[86],"2023-10-25",[3202],"Advanced Malignant Tumor",[3190],{"trials":3205,"activeCount":12},[],{"trials":3207,"activeCount":12},[],{"trials":3209,"activeCount":12},[],{"trials":3211,"activeCount":12},[]]